

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the)	
application of: Victor Casaña Giner, et al.)	
Serial No.: 10/596,556)	Confirmation No.: 7869
Filed: June 16, 2006)	Group Art: 1614
Title: CONTINUOUS MULTI-)	
MICROENCAPSULATION PROCESS)	
FOR IMPROVING THE STABILITY AND)	
STORAGE LIFE OF BIOLOGICALLY)	
ACTIVE INGREDIENTS)	

REQUEST FOR REPUBLICATION

Applicants request republication of their patent application to correctly list all inventors of record.

1. The patent application was published on April 5, 2007 under publication number US-2007-0077308-A1 (copy attached).

2. The publication listed only the first named inventor.

3. The official filing receipt dated April 11, 2007 correctly lists all four inventors of this application (copy attached).

4. All four inventors were correctly named in the Declaration filed with the United States Patent & Trademark Office on June 16, 2006 (copy attached).

4. The names of the four inventors that should be listed on the publication are:


- Victor Casana Giner
- Miguel Gimeno Sierra
- Barbara Gimeno Sierra
- Martha Moser

Applicants respectfully request republication with all inventors listed. Pursuant to 37 CFR § 1.221, Applicants include a copy of the application.

The Commissioner is hereby authorized to charge the republication fee of \$300.00 (§ 1.18(d)) and the processing fee of \$130.00 (§ 1.17(i)) to Deposit Account No. 22-0259. Authorization is hereby made to charge any additional fees required for this petition or credit any overpayment as authorized above to Deposit Account No.22-0259.

Respectfully submitted,

Dated: November 16, 2007

By: 
Michael J. Turgeon
Reg. No. 39,404

Vedder, Price, Kaufman & Kammholz, P.C.
222 North LaSalle Street
Chicago, Illinois 60601-1003
(312) 609-7716



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/596,556	06/16/2006	Victor Casana Giner	38438.00.0002

CONFIRMATION NO. 7869

23418
VEDDER PRICE KAUFMAN & KAMMHOLZ
222 N. LASALLE STREET
CHICAGO, IL 60601

Title: CONTINUOUS MULTI-MICROENCAPSULATION PROCESS FOR IMPROVING THE STABILITY AND STORAGE LIFE OF BIOLOGICALLY ACTIVE INGREDIENTS

Publication No. US-2007-0077308-A1

Publication Date: 04/05/2007

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently <http://www.uspto.gov/patft/>.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently <http://pair.uspto.gov/>. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 703-305-3028.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
10/596,556	06/16/2006	1614	750	38438.00.0002	28	4

CONFIRMATION NO. 7869

23418
VEDDER PRICE KAUFMAN & KAMMHOLZ
222 N. LASALLE STREET
CHICAGO, IL60601

FILING RECEIPT

Date Mailed: 04/11/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Victor Casana Giner, Ebenfurth, AUSTRIA;
Miguel Gimeno Sierra, Ebenfurth, AUSTRIA;
Barbara Gimeno Sierra, Ebenfurth, AUSTRIA;
Martha Moser, Ebenfurth, AUSTRIA;

Power of Attorney: The patent practitioners associated with Customer Number 23418

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/ES04/00562 12/17/2004

Foreign Applications

SPAIN P200302998 12/18/2003

If Required, Foreign Filing License Granted: 12/22/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/596,556**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Preliminary Class

534

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

DECLARATION AND POWER OF ATTORNEY

We,

- **CASAÑA GINER, Victor**, residing at Haschendorf RH 86/5; A-2490 EBENFURTH (Austria) and having a post office address of Gewerbezone 1, Ebenfurth, AUSTRIA. Citizen of Spain

- **GIMENO SIERRA, Miguel**, residing at Pottensteinerstraße 20A ; A- 2560 Berndorf, (AUSTRIA) and having a post office address of Gewerbezone 1, Ebenfurth, AUSTRIA. Citizen of Spain.

- **GIMENO SIERRA, Barbara**, residing at Pottensteinerstraße 20A ; A- 2560 Berndorf, (AUSTRIA) and having a post office address of Gewerbezone 1, Ebenfurth, AUSTRIA. Citizen of Austria.

- **MOSER, Martha**, residing at A-2734 Puchberg am Schneeberg, Neunkirchner Straße 48 (AUSTRIA) and having a post office address of Gewerbezone 1, Ebenfurth, AUSTRIA. Citizen of Austria

; We believe that we are the original, firsts and soles inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"CONTINUOUS MULTI-MICROENCAPSULATION PROCESS FOR IMPROVING THE STABILITY AND STORAGE LIFE OF BIOLOGICALLY ACTIVE INGREDIENTS"

the specification of which is being filed concurrently herewith, and identified by Attorney Docket No. 38438.00.0002.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendments referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) and (f) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: PCT/ES2004/000562.

We hereby claim the benefit under Title 35, United States Code, Section 119(e) or 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: NONE.

The undersigned hereby appoints Angelo J. Bufalino, Reg. No. 29,622, James T. FitzGibbon, Reg. No. 20,592, Richard A. Zachar, Reg. No. 25,560, Robert S. Beiser, Reg. No. 28,687, Christopher J. Reckamp, Reg. No. 34,414, Mark A. Dalla Valle, Reg. No. 34,147, Michael J. Turgeon, Reg. No. 39,404, Christopher Moreno, Reg. No. 38,566, and Alain Villeneuve, Reg. No. L-215, his attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, and to receive the Letters Patent. Please address all correspondence to:


Michael J. Turgeon, Esq.
VEDDER PRICE KAUFMAN & KAMMHOLZ, P.C.
222 N. LaSalle Street
Suite 2500
Chicago, Illinois 60601

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made herein of his information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Dated: 6.06.2006




MOSER, Martha



CASAÑA GINER, Victor



GIMENO SIERRA, Barbara



GIMENO SIERRA, Miguel

* * * *

[END OF DECLARATION AND POWER OF ATTORNEY]

Title

Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients.

Abstract

The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop –containing optionally oil-soluble materials- there is a dispersion of water, or aqueous extract or water dispersible material or water soluble material. The oil drops are encapsulated with a polymerisable material of natural origin. Such microcapsules are appropriated for spray-dry processes, to be used as dry powder, lyophilised, self-emulsifiable powder, gel, cream and any liquid form. The active compounds included in the microcapsules are beneficial to the health and other biological purposes. Such formulations are appropriate to be incorporated in any class of food, specially for the production of nutraceuticals, as well as cosmetic products (such as rejuvenescence creams, anti-wrinkle creams, gels, bath and shower consumable products and sprays). The preparations are adequate to stabilise compounds added to the food, media for cultivating microbes and nutraceuticals, specially those which are easily degradable or oxidizable.

Description

Notes:

Use of special terminology:

An expression than contains "A, B and/or C" means that permits the combinations A, A+B, B, C, A+C, B+C, A+B+C and its permutations.

Abbreviations:

The following list consists in terms commonly employed in the field of the invention:

W= water

O= oil

W/O= emulsion water in oil

O/W= emulsion oil in water

(W/O)/W= emulsion water in oil in water

a.i.= active ingredient(s). In the present invention it means biologically active ingredient(s), except when it is evident from the text that the ingredients are used not for biological functions. The use of singular or plural it is deduced from the text

UV= ultraviolet light

FA= fatty acid, with a carbon chain of more than 6 carbons

SFA= saturated fatty acid

MUFA= monounsaturated fatty acid (1 unsaturated bond)

PUFA= polyunsaturated fatty acid (2 or more unsaturated bonds)

HUFA= highly polyunsaturated fatty acid (4 or more unsaturated bonds)

w-3= UFA omega-3, it is said, that contains at least an unsaturation in the third carbon when numbering the chain beginning from the opposite side of the carboxylic group

w-6= UFA omega-6, defined as w-3, except in that the first unsaturation (at least one) when numbering the chain beginning from the opposite side of the carboxylic group, is in position 6 instead of 3.

The abbreviations w-3 and w-6 are referred either to the singular or plural case; FA, SFA, UFA, MUFA, PUFA, HUFA may be ended in "s" (e.g. HUFAs) when they are referred to plural case.

GMOs= Genetically modified organisms

The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop –containing optionally oil-soluble materials- there is a dispersion of water, or aqueous extract or water dispersible material or water soluble material. The oil drops are encapsulated with a polymerisable material of natural origin. Such microcapsules are appropriated for spray-dry processes, to be used as dry powder, lyophilised, self-emulsifiable powder, gel, cream and any liquid form. The active compounds included in the microcapsules are beneficial to the health and other biological purposes. Such formulations are appropriate to be incorporated in any class of food, specially for the production of nutraceuticals, as well as cosmetic products (such as rejuvenescence creams, anti-wrinkle creams, gels, bath and shower consumable products and sprays). The preparations are adequate to stabilise compounds added to the food, media for cultivating microbes and nutraceuticals, specially those which are easily degradable or oxidable.

Field of the invention.

The field of the invention corresponds to methods of formulation, use of biologically active materials, specially in foodstuffs, more specially in nutraceuticals of functional foods, comprises method of microencapsulation, microcapsules produced thereof and application (use) of them when they include certain compounds, some of them described in this document for the first time.

State of the Art

Microencapsulation

The microencapsulation technique is known and used in many fields (pharmacy, agrochemistry, dyestuffs, etc). There exist different forms to microencapsulate compounds in such a way they are controlled released. For a thorough and correct definition of the term microcapsule, and a broad prior art, check Fong, M. "Technologies of microencapsulation" in "Controlled Release Systems: Fabrication Technology, 1988 Vol I, Editor Dean Hsieh, CRD Press, Florida. There is explained that often is confounded the term "microcapsule" must not be confounded with other formulation methods as emulsions, microspheres, liposomes, etc. "True" microcapsules (what we call microcapsules in this

invention), are based in a physical separation of phases by means of a wall (polymer) that has inside - the "core"- the microencapsulated material. "True" microencapsulation (the one referred to in this invention) must be not confounded the technique of formulate materials by dispersing or mixing them in polymeric matrices (without a clear physical separation of phases). Care must be taken to avoid considering microcapsules as simple emulsions. There is a huge amount of literature (patents and scientific papers) regarding matrix encapsulation, as well as emulsions W/OW (water in oil in water), W/O (water in oil) and O/W (oil in water). A fundamental differentiation of the present invention with all the previous patents referring to true microcapsules (hereinafter, microcapsules) is that we create an emulsion W/O that is enclosed by a microcapsule's wall, and these microcapsules are dispersed or emulsified in water, moreover, the microcapsules can contain smaller microcapsules in the core, thus having multi-microcapsules. On one side, the microcapsules here disclosed (and their production method) are characterized in that the wall is made of a mix of hydrocolloids that are polymerized and cross-linked and the hardening of the structure is due to an increase in temperature, the process runs without time laps in between process steps and under continuous agitation. No patent or scientific paper discloses a microencapsulation method similar to this one.

No patent or scientific paper discloses a microencapsulation method similar to ours. The closest state of the art regarding this invention is represented by US 6,234,464,

US 6,234,464 describes a method of microencapsulation of FA (Fatty Acids). Differences with respect the present invention are: i) in US 6,234,464 the core of the microcapsule has only an O (oil) phase; in our invention the core has a W/O phase ii) in US 6,234,464 the core contains no multi-microencapsulated drops; in our invention the core contains (as statistically distributed) microcapsules inside of the core of bigger microcapsules iii) in US 6,234,464 the wall is limited to two hydrocolloids, further separated and differentiated into two layers; in our invention is possible and convenient to combine more than two hydrocolloids and there is no differentiated layered structure iv) in US 6,234,464, during the process disclosed in example 1, the process includes a pH change step and a cooling step to harden the microcapsules; in our invention, hardening is done by increase of temperature at the end of a continuous process, because there is no need to form a "first layer" and later a "second layer" (we allow all the hydrocolloids to polymerize and cross-link together) v) in US 6,234,464 are not in contact with any other compound; in our invention it is recommendable that either in the oil phase or in any of the two water phases, stabilizers and antioxidants are used vi) the hardening step done in US 6,234,464 is by done means of cooling; while we use increase of temperature, and in our case the wall is strenhgher vii) in US 6,234,464 for obtaining dry microcapsules and remve water from the walls, it is used ethanol; in our invention it can be obtained dried microcapsules (in powder form) without the use of ethanol.

Although the differences mentioned are many, they make reference to the process; the microcapsules formed thereof also present rather different characteristics, in particular regarding thermal properties, controlled release of active ingredients (US 6,234,464 refers only to FA), etc. Any other disclosed process of microencapsulation and microcapsules produced thereof differ from our invention even more than US 6,234,464.

Use of FA in foodstuffs

It is known for the skilled in the art that certain UFAs are ealthy, inparticular MUFAs, PUFAs and HUFAs. We can differenciate w-3 and w-6. Following publications of scientist and epidemiological studies many patents have been filed afterwards, that, based on such studies, that claim the use of these natural compounds, that have been consumed by the humankind since its beginning. The inventors of this patent do not know any patent that claims the combined use of FA with sphingolipids either with cerebrosides.

The methods of application of all these compounds are widely varied, including microencapsulation but not even similar to the one herein described (that is characterized in that allows to incorporate to any kind of foodstuff microencapsulated UFAs without a significant degradation of them).

It is described the combination of UFAs with antioxidants (EP 404058, US 5,855,944) but in no case are used microcapsules as those described herein, and lack any sound reseach on the quality of the UFAs one the foodstuff is industrially processed (namely, no degradation of UFAs), or just the shelf-life stability.

There exist many sources of UFAs, practically all of them described in scientific papers before being claimed in patents. The novelty of this patent is not referred to the sources of the UFAs, rather in the microencapsulation of UFAs obtained from natural sources (or GMOs), or by organic syntheses, in microcapsules for its use in foodstuffs and other uses.

Infant foods

A particular embodiment of this invention is the use of our formulation in infant foods. Cow's milk lacks of certain UFAs that are present in the mother's milk. This type of nutritional complementation has been elsewhere claimed, but no such disclosure has been made with regard of microencapsulated materials and the optimal conservation of the UFAs till final consume (WO 9213086).

Intelligence development

It is a nowadays debate the increase of intelligence, or at least the potential intelligence, by DNA recombinant techniques. The inventors, based in diverse scientific papers that describe the development of the brain cortex (where the intelligence resides) with a correct and balanced consume of UFAs w-3, w-6 and w-9, as well as the role of certain sphingolipids in neuronal transmissions, and knowing human metabolic pathways, have found a solution for a new demand of the society: to develop to the maximum extent the potential of the human, in particular the intelligence, as the distinctive feature of the humankind, by addition of certain natural compounds to the diet. We describe here the combined use of w-3, w-6 and w-9 and sphingolipids, in particular cerebrosides to increase the potential development of the intelligence, The inventors are not aware of such use of compounds for the aforementioned purpose, lesser in the form of microencapsulated material, and much lesser in microcapsules as herein described. There is already scientific evidence for the use of w-3 and w-6 and w-9 in regard intelligence (but not combined with sphingolipids or cerebrosides for brain development). See Biol. Neonate 1998, 74:416-429 and "Evidence for the unique function of DHA during evolution of

the modern hominid brain", *Lipids* 1999, vol. 34(S):S39-S47. The latter points out to the role of DHA in the development of intelligence from hominids to humans.

Use of antioxidants, protectors and blockers of UV-light, and free-radical blockers.

It is well known that the origin of many illnesses, from cancer till cataracts is due to oxidation reactions, degradation of DNA chains due to oxidation processes and induced by oxidants, UV-light and or free radicals. Many inventions relate to the use of natural antioxidant extracts, antioxidant compounds, etc (EP 1344516, EP 1064910) to prevent a wide array of diseases. However, the present invention achieves the needed fact that the antioxidant compounds or extracts preserve their antioxidant capacity through industrial processes and strong stressing environments, until the consumer gets the compounds in a perfect quality and functional state (not degraded), thanks to our microencapsulation technology.

Detailed description of the invention

We refer to a continuous multi-microencapsulation process, and microcapsules thereof and their uses, by means of in situ interfacial polymerization of biologically active materials characterized in that,

- (a) in a first step it is added to an oil phase [that contains optionally at least a biologically active material] a water phase containing a polymerization initiator and optionally, at least a biologically active material; further exists at least one surfactant in at least one of the two mentioned phases, and there exists a biologically active material in at least one of the two phases,
- (b) In a second step, it is added [to (a)] a solution or dispersion in water that contains at least one hydrocolloid, this producing a phase inversion and the hydrocolloid begins to be deposited and polymerized on the walls of the new formed drops [consisting in a water in oil emulsion], occurring also a cross-linking of the hydrocolloid polymers, optionally in the presence of cations,
- (c) In a third step, it is added [to (b)] a solution or dispersion in water that contains at least one protective colloid, that begins to be deposited on the surface of the drops of water in oil, and to polymerize and cross-link with itself and the hydrocolloid,
- (d) In a fourth step, it is added [to (c)] a solution or dispersion in water of a primary surfactant that allows a reduction of the size of the water in oil drops,
- (e) In a fifth step, during the process of reduction of size, the partially formed microcapsules are deagglomerated and reagglomerated, happening eventually an enclosure of drops inside bigger drops (multi-microencapsulation),
- (f) When enough time has passed in order that the oil [water in oil] drops are covered by at least one hydrocolloid and at least a protective colloid, the temperature is increased in order to strengthen the wall of the mentioned drops; at this time the drops are already microcapsules or multi-microcapsules suspended in water.
- (g) Optionally, the formulation is dried for obtaining dust, optionally it is reformulated by means of state of the art techniques to obtain (or to mix the microcapsules with) wettable powders, gels,

cosmetic creams or medicinal, bath products, microorganism media; optionally additives are added (optionally antiagglomerating agents) for microcapsules' dried formulations.

(h) All the process –except optionally step (g)- is carried out under continuous agitation.

In a more detailed description of the process, referred to the Figures, that is an alternative description with the same subject matter, and referring to the drawings we refer to a process for the preparation of microcapsules characterized in that:

- (a) Two different solutions (Fig.1) 1a (oil) and 1b (water) are mixed by addition of 1b to 1a, these solutions containing active ingredients and optionally free or sequestered cations to be liberated later,
- (b) Thanks to a food emulsifier that can be in 1a or in 1b, an emulsion of water drops (10) into the oil phase (9) is formed. This step is finished with the formation of emulsion 1c, where in the oil phase (9) are solubilized or dispersed –preferably liposoluble- active ingredients; it is also formed an oil in water emulsion, with the water droplets (10) containing –preferably hydrosoluble- active ingredients, being optional that the solubility [of the active ingredients] in water or in oil is modified by derivatization of the active ingredient(s),
- (c) Then, it is added to existing emulsion [1c] the solution 2b, having 2b at least one hydrocolloid [able to be polymerized and cross-linked] and optionally containing at least one active ingredient,
- (d) It follows a phase inversion, having then dispersed drops (11) that are an emulsion of water (12) in oil, dispersed in the continuous phase (24), namely, water,
- (e) Later, (Fig. 5) it is added a solution or dispersion 5a, containing at least a hydrocolloid (15) that acts as protective colloid, The solution or dispersion containing the primary emulsifier is added to emulsion 2a.
- (f) when the polymerization and cross-linking reactions are deemed to be finalized, reaching a reduction of particle size to about 1-30 m, the temperature that remained at about 30-70 °C is raised to 60-100 °C.
- (g) Finally it is added a food grade viscosity modifier.
- (h) Optionally, the formulation may be spray-dried or any state of the art technique, and to be collected to form dry powders, self-emulsifiable powders, gels, creams or any other form that may contain them, including oil dispersions, as well as to be submitted to a lyophyllization unit operation.

We also refer to process of microencapsulation of biologically active materials

Preferred embodiment of the invention

Since the preferred embodiment is the use of the microcapsules to add to functional foods, the microcapsules have been submitted to tests against thermal, pressure and pH in specific ranges degradation.

The hydrocolloid(s) as well as the protective colloid(s) may be added together in the form of a solution or aqueous dispersin initially.

The primary emulsifier and the protective colloid can be chosen in between the group of hydrocolloids, as well as the viscosity modifier, because the hydrocolloids possess all these features.

The group of compounds more adequate for a successful formulation (functionally acceptable, it is said, it serves for a functionally acceptable encapsulation of biologically active ingredients and also to other living or mineral materials, in the way that functionally acceptable is understood as industrially usable for the purposes for what the materials have been microencapsulated, each functionality is highly dependant in the final use) according the described process corresponds to chitosans, starches, dextrans, cyclodextrins, celluloses, lignines, pectines, agar alginates, carragenates, gelatins, guar gum, Arabic gum, tragacanth, lignosulfonates, Caravan gum, Ceratonia siliqua gum, saponines, Xanthan gums, seeds' gums, galactomanans, arabanogalactomanans, beta-glucanes, inulin, Psyllium, acacia gum, in all their isomeric and stereochemical configurations, in all their variations regarding quantity and quality of monomers or oligomers that constitute the hydrocolloid, in all their presentation forms, as metal, nitrogenated, phosphorated, sulfurated salts, as well all the derivatized products of the referred hydrocolloids.

The hydrophylic-lipophylic value (HLB) of the primary emulsifier can be conveniently chosen in between 9 and 16, preferably in between 12 and 14.

The emulsion 1c (10) typically has a particle size (a Master Sizer[®] laser equipment is referred for all particle size measurements) of 50-500 μm , preferably 70-200 μm .

At the end of the process, the formed microcapsules have a size of 0.1-100 μm , preferably in the range 1-30 μm , more preferably 1-5 μm . This size may vary with time with aggregation processes that in to some extent may be desirable as far as the total structure of the formulation is not affected.

The shear stress to reduce the particle size of the emulsion and normal agitation is given by state of the art agitators (anchor, teeth, combinations) and by an approximate speed of 3000 to 25000 rpm. These values depend on the stage of the process and the dimension of reactors. Once the microcapsules are formed is not recommended to provide too much kinetic/thermal energy, in order to avoid microcapsules' destruction.

Particular types of colloids are the hydrogels, and then the hydrocolloids may be substituted by hydrogels optionally based in albumin, alginates, polycarboxylates, poli-L-lactid, starch and derivatives. We can choose, according the experimentally measured release rate (influenced by the media, e.g., yogurt) different combinations of hydrocolloids, changing the degree of polymerization, the hardness of the wall, the thickness of the wall and permeability (to determined type of materials) and electric properties.

This variability of the wall forming materials is also applicable to the viscosity modifiers and emulsifiers either the one(s) used to form (1c), preferably a polysorbate) as a primary emulsifier (preferably a soy lecitin based emulsifier).

The microcapsules may be obtained in a dry state, or to be redispersed in liquid phases or solid and solidifiable matrices. The outer media of the microcapsules may have compounds that help to maintain the wall structure, like ionic force regulators, osmotic pressure, etc. It is possible that inside the microcapsules there are present metallic cations that once formed, help in maintaining the structure, like Calcium ions inside a microcapsule's wall made with pectins.

The active ingredients may be added in any step of the process, including the phase of the process when the foodstuff is mixed with the microcapsules, but, obviously, is preferred that the materials are incorporated inside the microcapsules. Then, the active ingredients may come from solutions 1a, 1b, 2b, 5a or be added in any step of the final food process, when the microcapsules are previewed to be used in foodstuffs, that is a preferred embodiment of the invention (functional foods).

It is important to prevent oxidation processes (e.g., for UFAs and antioxidants). Then, the process may be conveniently performed under vacuum, in the presence of an inert gas (nitrogen, helium), protected from light of any wavelength and in sterile conditions.

We refer to water phase in this document to solutions or dispersions -apart from water alone- to those: (i) based in aqueous extracts (ii) with a content in alcohols lower than 40% being the rest water (iii) compounds soluble or dispersible in water (better explained, polar substances).

It must also understood that the oil phase is referred to any hydrophobic phase that is functionally acceptable (it leads to stable formulations, able to be incorporated in foodstuffs or used for other specific applications achieving the expected success), as it can be honey or waxes.

It must be also considered that the thermal properties of the water or oil phase may be modified to decrease the thermal stress inside and outside of the microcapsules, by virtue of the different thermal properties of water, alcohols or oils, as well as the transmission coefficients from phase to phase. The accumulation of thermal energy by the solutions and dispersions inside and outside of the microcapsules may be used to protect the active ingredients from deterioration. It can be added food grade microbiological stabilizers.

One embodiment of the invention refers to dry microcapsules covered by a microbiological stabilizers. For certain applications, particularly cosmetic ones, once the microcapsules are dry (or even in wet form) they can be added in gels, oils, alcoholic solutions for perfumes, etc. In an embodiment of the invention, the microcapsules contain flavours (aromas) to be used in perfumery or to provide perfumes to gels and bath creams or soaps.

The microcapsules can be applied to all type of foods, in a non restrictive way the following examples: cereals and derived (optionally muesli, cereals for milk), pastry shop, dairy products, nutritional supplements, sugars and derived (optionally chocolates, sweet, nougats, marzipans), sweet dietary (with low level of calories), in régime foods and for diabetics, oils and derived, milky and derived, eggs, vegetables and vegetables, vegetables, fruits, tubers and derived, eatable shafts, snacks, appetizers, eatable roots (optionally licorice), bay and wild products, preserves of fruits, dry fruits, meats, sausages, fish, shellfish and crustaceans and their preserves, alcoholic and not alcoholic drinks, carbonated drinks or not carbonated, juices, syrups, nectars, spices, condiments, pre-cooked foods, pre-processed foods (frozen mass of bread), pizzas, honey.

Although the main and more useful embodiment of the invention refers to feeding (of human and other animals, even fish and also microorganisms), the microcapsules can be employees for other purposes, in particular to encapsulate semiochemicals, attractants, repellent, insecticides, sterilizers, herbicides, fungicides, germicides, viricides (or materials that prevent the viral infections), vectors of genes (for gene therapy or for objectives of technical of recombinant DNA), aromas, indicatives of presence of compounds -as mixed in gas or liquids-, toilet chemicals, astringents to avoid the ingestion of toxic products also in household products. The invention can be carried out to avoid

aromas, with the adaptation of the materials of the wall and other factors, in order to avoiding to the maximum the liberation of the encapsulated materials. This is especially useful for products enriched with omega-3/-6/-9 coming from fish oils, in such a way that the non-desirable scents are reduced to the minimum.

In an example presented later on, we will see that the applicant has used advanced statistical techniques usual to reduce the number of necessary tests to determine the most appropriate parameters to encapsulate certain compounds, or to obtain the speed of wanted liberation, etc. to select the independent variables: type of made up of the wall, particle size, emulsifiers(s), speed of rotation of the agitator, agitator type, modifier of viscosity, etc. and an independent variable that represents the quality of the formulation or of the microcapsules. This type of reduction of trials to reproduce the invention is recommended due to the high number factors involved in the repetition of the invention. It has been used the variance analysis or multiple variance analysis with design of factorial fractions, preferably factorial in 2, 4, 8, 16, 32, and 64 blocks, half saturated fraction, I design Box-Behnken, central compound, Plackett-Burman. The present invention is the five year-old result with more than 50,000 different formulations, however, without the employment of these statistical techniques, the number of rehearsals would ascend to, at least, a bigger number in 10 orders of magnitude.

Defining an aspect of the invention we can refer to the microcapsules taken place by means of a continuous process of multi-microencapsulation characterized because (a) they contain beneficial active ingredients for the human health; (b) the wall of the microcapsules is composed of a mixture of at least two hydrocolloids, such a mixture polymerized and cross-linked, such hydrocolloids are eatable; (c) the polymerization degree, cross-linking and nature of the hydrocolloids influence the controlled liberation of the active compounds and the protection against the oxygen and/or light and/or temperature; (d) the microcapsules contains in their interior an emulsion of water in oil, existing active ingredients optionally in the phase oils, optionally in the phase it dilutes or optionally in both phases and also, (e) they can contain smaller microcapsules (multi-microencapsulation possible until, at least, 5 degrees of multi-encapsulation); and the particle size of the microcapsules is in the range 0,1 μm - 100 μm , preferably in the range 1 μm - 10 μm (f) they are produced by means of a continuous process of multi-microencapsulation for polymerization interfacial in situ.

The microcapsules formed according to the process described, can liberate their content for reasons of at least an elected factor of the group of: pH, temperature, pressure, ionic force, osmosis, volatilization, presence of compounds that dissolve the wall of the microcapsule.

The formed microcapsules, in an embodiment corresponding to human consumption, they should resist the usual alimentary industry processes, in particular to operations, belonging to the state of the technique, concerning to protection against microorganisms, noxious and/or unwanted compounds presence, microorganisms settlers of the formulation or food to which is dedicated, and the invention provides microcapsules able to be submitted to unit operations like: sterilization, stabilization of microorganisms, pasteurization, UHT, ozonization, UV and gamma ray treatments, sterilizing irradiations.

In another embodiment, the formulation is accompanied with a certificate of quality where the nonexistence of heavy metals is analyzed, noxious products of degradation of the biologically active

materials, agrochemical products used in the production of the compound biologically active and other materials that are noxious for the health.

In another embodiment of the invention, the microcapsules are used to provide nutritive anabolites, compounds that help to identify causing microbes of illnesses (as selective anabolites or radio-active fluorescent or marked products), and these compounds optionally can be liberated by pH changes in the means of cultivation (p. e.g., agar potato-dextrose), for production of enzymes (of the same microbial cultivation, p.ej.) or other metabolites (as alcohol or liberated enzymes).

The microcapsules can be added to natural or artificial sweeteners, salt, pepper, spices and condiments in general, in such a way that the addition of the mentioned condiments to the foods makes that the nutritious value is increased, or the benefit for the health of the foods.

For a bigger protection of the wall of the same microcapsula, or the contained active compounds in it, it is convenient to include compound(s) inside or outside of the microcapsule that prevent the oxidative action of the ultraviolet rays.

A favorite embodiment is that in the one that the material to be microencapsulated are compounds that are known by the scientists and for the public as very appropriate to maintain the health or to prevent illnesses, or even to cure illnesses. Nevertheless, when considering the number of patents that claim the use of certain compounds (antioxidants and acids fatty omega-3, omega-6 and w-9 mainly), it is necessary to have present that the an overwhelming percentage, these patents have been requested after the beneficial effects of these compounds were described by the scientific community in articles and conferences. It is then, the objective of our invention, to apply well-known compounds as healthy in microencapsulated form since our microencapsulation method is able to maintain until the final consumption by the consumer or of any other animal, all the beneficial properties of the active compounds (to avoid its degradation). The practical entirety of products which are described in this patent, have been described as beneficial for more than 20 years, or even used consciously by the humanity or unconsciously for its benefits for millennia, and even from the origins of the mankind. In this sense, the inventors choose the non-limiting group of compounds, (in combinations or partially or used individually), to be microencapsulated as the following: green tea, black tea, cocoa, red wines or red grapes or residues of grapes (pomaces and marcs), cider or apple or apple juice, germ or saved of cereals, carrots, chili, garlic, radish (especially, spicy radish), as a for long time used foodstuffs.

In the same way it has been already explained, the present invention allows the formulation of a variety of material types, being novel that the microencapsulated materials are microencapsulated with edible materials, and protect from degradation in the industrial processes or the kitchen, in a much higher degree than what is prior art, thanks to the structure of the multi-microcapsule. After the high number of experiments performed by the inventors, and considering that the chemically similar compounds behave similarly in the process and in the microcapsule (e.g., pineno and limonene, being both monoterpenos, must present no difference at the time of microencapsulation either at the time of their release, even copaene, that is a sesquiterpeno, won't differ much from the monoterpenos, either limonene oxide, with an additional functional group, because fuctional groups does not affect the formation of the microcapsule, either in the emulsion formation in a drastic way. In those cases where compounds may affect to the process as the need of

special emulsifiers, the inventors have foreseen for cases, where different emulsifiers, polymers, etc. are used, and limited to those already mentioned –but able to overcome any difficulty in the process of encapsulating the following compounds or materials):

- (a) Flavonoids in general and derivatives: anthocyanidins, pro-anthocyanidins, oligomer-procyanidine, isoflavones, chalcones, catechin, epihatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, eriocitrin, narirutin, rutin, naringin, myricitrin, hesperidin, myricetin, eriodictyol, fisetin, quercetin, naringenin, luteolin, hesperidin, kaempferol, isorhamnetin, apigenin, rhamnetin, galangin, quercitrin, quercetin, diosmetin, taxifolin, galandin, biochanin A, genistein, eriodictyol, chrysin, hydroxytyrosol, oleuropein, gabardine, licochalcone, daidzein, matairesinol, secoisolariciresinol, enterodiol, enterolactone, equol, desmethylangolensin, luteoferol, luteolinidin, apiferol, apigenidin, leucocyanidin, taxifolin, pelargonidin; and derivatives thereof;
- (b) phenolic acids in general and derivatives (preferably esters, glycosides, rutinosides and amines): gallic, sinapic, syringic, caffeic, chlorogenic, ferulic, (o-, m- or p-) coumaric, guaiacol, (o-, m- or p-) cresol, 4-ethylphenol, 4-vinylguaiacol, eugenol, p-hydroxybenzoic, procatechuic, vanillic, hydroxycinnamic, tanins in general tannins, ellagiotannins, gallotannins; and derivatives thereof;
- (c) esctructurally combined amides comprising hydroxycinnamic acids and anthranilic acids (avenanthramides), avenasterol, hydroxycinnamic acids and long-chain fatty acids or alcohols –and derivatives thereof-; indoleamines (e.g. melatonin); inulin, glutation;
- (d) terpenoids in general and derivatives, monoterpenes, diterpenes, sesquiterpenes, triterpenes, tetraterpenes including the carotenoids: alfa-carotene, phytoene, cyclo-artenol, beta-carotene, ionone, zeaxanthin, capsanthin, astaxanthin, canthaxantin, violaxanthin, mutatoxanthin, luteoxanthin, auroxanthin, neoxanthin, apo-carotinal, xanthophylls; and derivatives thereof;
- (e) commonly synthesized antioxidants for its use in foodstuffs and derivatives of the type of butylhydroxyanisol, 2,6-di-tert-butylhydroxytoluene, tert-butylhydroquinone, 2,6-di-tert-butylhydroquinone, 2,6-diterbutyl-4-hydroxymethylphenol, 2,4,5-trihidroxi-butyrophenone; and derivatives thereof, tocopherols (e.g. alpha, beta, gamma and delta tocopherols –and derivatives thereof-; Tocotrienols (alpha, beta, gamma and delta tocotrienols –and derivatives thereof-); Tocochromanols;
- (f) alpha-lipoic acid; coenzyme Q-10; vitamins; aminoacids (preferably L-arginine, cistina and cysteine) and their corresponding organic polymers like oligopeptides, peptides –preferably carnosine, carnitine, glutathion-; enzymes; enzyme inhibitors (preferably phenolases or oxigenases or lipooxygenasas or lipases inhibitors;
- (g) minerals and oligoelements, especially those involved in redox processes in vivo like selenium, zinc, magnesium.

The natural sources where the above compounds (or other compounds not yet known or already known but not mentioned in the natural sources above) may be selected -considering state of the art methods of extraction of any interesting material (in pure or mixed form, in any physical state)- can be

selected from accepted vegetal additives for its use in foodstuffs, considering additives something that is added to the foodstuff, being a predominant or fundamental part of the foodstuff or not. Some narcotic-producing plants are considered by the inventors able to be used in medicine. Finally, in the following list are listed plants with known therapeutic properties and used in herboristery and par-pharmacy. This is a list of non-limiting examples of natural a.i. to be microencapsulated, either by isolation of compounds, by aqueous or alcoholic solutions, also dispersions of leaves, roots, stems, flowers fruits, etc., grinded till certain suitable particle size, and also lyophilized preparations of such a.i. or preprocessed in any form. The list, in a non limiting sense is:

Medicago sativa, *Pimpinella anisum*, *Ferula foetida*, *Ferula asafetida*, *Melissa officinalis*, *Myroxylon pereirae*, *Ocimum basilicum*, *Pimenta acris*, *Citrus aurantium bergamia*, *Prunus amygdalus*, *Citrus aurantium*, *Citrus aurantium amara*, *Piper nigrum*, *Prunus spinosa*, *Aniba rosaeodora*, *Camelia oleifera*, *Camelia sinensis*, *Carum carvi*, *Elettaria cardamomum*, *Ceratonia siliqua*, *Daucus carota*, *Dacus carota sativa*, *Cascarilla*, *Apium graveolens*, *Anthemis nobilis*, *Matricaria chamomilla*, *Anthemis nobilis*, *Anthriscus cerefolium*, *Cichorium intybus*, *Cinnamomum* spp., *Cinnamomum zeylanicum*, *Cymbopogon nardus*, *Salvia sclarea*, *Trifolium pratense*, *Theobroma cacao*, *Coffea arabica*, *Coriandrium sativum*, *Cuminum cyminum*, *Taraxacum officinale*, *Sambucus nigra*, *Edelweiss*, *Helichrysum italicum*, *Foeniculum vulgare*, *Trigonella foenumgraecum*, *Arabidopsis* spp., *Zingiber officinale*, *Citrus grandis*, *Psidium guajava*, *Humulus lupulus*, *Marrubium vulgare*, *Monarda punctata*, *Hyssopus officinalis*, *Jasminum officinale*, *Jasminum grandiflorum*, *Juniperus* spp. *Juniperus communis*, *Eucalyptus officinalis*, *Cola acuminata*, *Laurus nobilis*, *Lavandula* spp. *Lavandula hybrida*, *Taxus baccata*, *Citrus medica limonum*, *Myristica fragrans*, *Marjorana hortensis*, *Thymus* spp., *Thymus officinalis*, *Thymus mastichina*, *Ilex paraguarensis*, *Chamomilla recutita*, *Saccharum officinarum*, *Myristica fragrans*, *Allium cepa*, *Citrus aurantium dulcis*, *Carum petroselinum*, *Mentha pulegium*, *Mentha piperita*, *Pimenta officinalis*, *Chimaphila umbellata*, *Punica granatum*, *Pelargonium* spp., *Pelargonium graveolens*, *Rosmarinus officinalis*, *Crocus sativus*, *Salvia* spp., *Salvia officinalis*, *Mentha spicata*, *Mentha viridis*, *Satureia hortensis*, *Satureja hortensis*, *Origanum majorana*, *Tamarindus indica*, *Citrus reticulata*, *Artemisia dracunculus*, *Thea sinensis*, *Thymus vulgaris*, *Polianthes tuberosa*, *Curcuma longa*, *Prunus serotina*, *Thymus serpyllum*, *Satureja Montana*, *Cananga odorata*, *Curcuma zedoaria*, *Plantago major*, *Adansonia digitata*, *Ananas comosus*, *Artocarpus altilis*, *Carica papaya*, *Lycopersicon esculentum*, *Cephalophus* spp., *Vaccinium myrtillus*, *Thymus aragonensis*, *Thymus* spp., *Citrus aurantiifolia*, *Citrus paradisi*, *Cucumis melo*, *Cucurbita* spp., *Vitis* spp., *Vitis vinifera*, *Mangifera indica*, *Lamiaceae* (*Coleus*, *Hedeoma*, *Hyptis*, *Leonurus*, *Leucas*, *Lycopus*, *Marrubium*, *Mentha*, *Monarda*, *Perilla*, *Prunella*, *Salvia*, *Stachys*, *Teucrium*, *Thymus*), *Cannabis* spp., *Digitalis lanata*, *Adonis vernalis*, *Aesculus hippocastanum*, *Fragaria vesicaria*, *Agrimonia eupatoria*, *Rauvolfia serpentina*, *Andrographis paniculata*, *Areca catechu*, *Atropa belladonna*, *Berberis vulgaris*, *Ardisia japonica*, *Betula alba*, *Ananas comosus*, *Camellia sinensis*, *Cinnamomum camphora*, *Camptotheca acuminata*, *Potentilla fragarioides*, *Erythroxylum coca*, *Papaver somniferum*, *Colchicum autumnale*, *Claviceps purpurea*, *Digitalis purpurea*, *Digitalis lanata*, *Glaucium flavum*, *Papaver somniferum*, *Gossypium* spp., *Hyoscyamus niger*, *Camptotheca acuminata*, *Piper methysticum*, *Lobelia inflata*, *Crotalaria sessiliflora*, *Nicotiana tabacum*, *Physostigma venenosum*, *Ephedra sinica*, *Cinchona ledgeriana*, *Rhododendron*


molle, *Datura* spp., *Taxus brevifolia*, *Strychnos nux-vomica*, *Stevia rebaudiana*, *Theobroma cacao*, *Valeriana officinalis*, *Pausinystalia yohimbe*, *Ephedra* spp. *Crataegus oxyacantha*, *Hamamelis virginiana*, *Hydrastis Canadensis*, *Hypericum perforatum*, *Potentilla erecta*, *Ledum palustre*, *Salvia officinalis*, *Chamomilla recutita*, *Arctostaphylos uva*, *Eucommia ulmoides*, *Mytilus galloprovincialis*, *Diplazium esculentum*, *Manihot utilissima*, *Sauropous androgynus*, *Terminalia arjuna*, *Iberis amara*, *Crataegus* spp., *Arbutus unedo*, *Cynara scolymus*, *Amaranthus caudatus*, *Alchornea laxiflora*, *Alpinia officinarum*, *Xanthophyllomyces dendrorhous*, *Crataegus monogyna*, *Taxus yunnanensis*, *Bacopa monniera*, *Cistus albidus*, *Ocimum basilicum*, *Rosmarinus officinalis*, *Thymus vulgaris*, *Bixa orellana*, *Centella asiatica*, *Urtica dioica*, *Agrocybe aegerita*, *Crataegus laevigata*, *Satureja hortensis*, *Crocus sativus*, *Coccinia indica*, *Brugia malayi*, *Rubus* spp., *Silybum marianum*, *Cannabis* spp., *Cannabis sativa*, *Hypericum perforatum*, *Rhus coriaria*, *Olea europaea*, *Cyclopia intermedia*, *Ginkgo biloba*, *Lentinus lepideus*, *Pseudomonas putida*, *Sargassum micracanthum*, *Pinus radiata*, *Pinus* sp., *Phaseolus mungo*, *Cicer arietinum*, *Vigna sinensis*, *Phaseolus aureus*, *Dolichos lablab*, *Cajanus cajan*, *Vicia faba*, *Dolichos biflorus*, *Phaseolus lunatus*, *Phaseolus aconitifolius*, *Pisum sativum*, *Psophocarpus tetragonolobus*, *Arachis hypoagea*, *Brassica* spp., *Brassica campestris*, *Brassica napus*, *Valeriana officinalis*, *Echinacea purpurea*, *Echinacea pallida*, *Echinacea angustifolia*, *Glycyrrhiza glabra*, *Seronea repens*, *Vaccinium macrocarpon*, *Tancetum parthenium*, *Tancetum parthenium*, *Vaccinium macrocarpon*, cereals, seed fruits, silvestre bays, leguminosae, green tea, black tea and microorganisms able to produce long-chained unsaturated fatty acids.

Another issue that is a social concern in developed countries is the consum of probiotic organisms, understanding such organisms as those that by virtue of their metabolism or by its presence in the (foreign) organism protect against infections (specially Candidasis), reduce cholesterol and glycerides levels and help digestion and intestinal movement. Usually these organisms are introduced in yogurts and other dairy products, but with our invention we are able to encapsulate living bacteria, yeasts and molds present in the so-called probiotic foodstuffs, and remaining alive after microencapsulation and processes of the food industry as homogeneization and pasteurization and certain types of cooking or house preparates. This implies a novelty in order to add this probiotic organisms to a lot of foodstuffs. Preferably we chose, not limiting, the organisms as follows: probiotic bacteria, optionally acid lactic-bacteria and more preferably chosen among the group: *Lactobacillus casei*, *L. acidophilus*, *L. rhamnosus*, *L. paracasei*, *L. gasseri*, *L. fermentum*, *L. plantarum*, *L. salivarius*, *L. crispatus*, *L. bulgaricus*, *L. fermentum*, *L. reuteri*, *Bifidobacterium infantis*, *B. bifidum*, *Streptococcus thermophilus*, *S. bovis*, *Enterococcus durans*, *E. faecalis*, *E. Gallinarum*, *Escherichia coli*, *Propionibacterium freudenreichii*, or bacteria or fungi or yeasts genetically modified in that the beneficial genes -characterizing the beneficial properties of probiotic bacteria- have been inserted and also a process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials present in the formulation consist in probiotic yeasts, preferably chosen from the group: *Saccharomyces cerevisiae*, *Kluyveromyces marxianus*, *Rhodotorula rubra*, *Sporobolomyces puniceus*, *Aureobasidium pullulans*, *Leucosporidium scotti* and also a process of microencapsulation characterized in that at least one of the biologically active materials present in the formulation consist in probiotic fungi, preferably those fungi present in or coincident or coming from cheeses.

The interest in omega 3/6/9 FA has been followed by a huge scientific community, and as well, by Governmentally, University and Medical driven research, proving the benefits of these compounds. Many patents are directed to protection of results that are inferred from such studies (that also include determined ratios of different types of omega FA). This invention is not directed to this patented field, rather to the use of our microcapsules to protect with an extraordinarily better performance in front of state of the art techniques. The inventors, in this regard, investigated the stability and the suitability for microencapsulation of a new type of chemical compounds formed by the esterification of UFAs with sphingolipids, and more precisely with cerebrosides, after consideration of its chemical and biological roles in the development of the brain and specially in the cortex (where the intelligence resides) and other places (e.g. retina). The combination of UFAs with cerebrosides do not have precedent to the best of our knowledge, lesser its use in a covalently bonded compounds (A) and (B), for example, synthesized by the inventor according a modified synthesis according Dondoni et al. (1990), J. Org. Chem. 55(5):1439-1446 and Schmidt and Zimmermann (1986) Tetrahedron 27 (4): 481-484.

We synthesized compound B, R3: CH₂CH₃, R4: CO-(CH₂)₂-(CH₂-CH=CH)₄-CH₂-CH₃, with a yield (based on initial arachidonic acid content) of 35%. Due to the small amount of compound synthesized we could only obtain LC-MS data (Agilent 1100 Series LC/MSD Trap) confirming that a peak had the characteristic fractionation peaks of the sphingolipids side together with a typical fragmentation of arachidonic acid (M/Z: 79, 67, 91, 55, 108, 318 [M+]). The analysis of the sphingolipids branch was analyzed also after esterification and benzylation. Also, we did not observe UV absorption at 205 nm, indicating thus that the double bonds remained without transisomerization. Results were similar when esterifying stearidonate with compound A, in position R₁, leading the synthesis to a R₂ consisting in H. Therefore, in the present invention we show amicroencapsulation method characterized in that at least one of the a.i. (biologically active material) is chosen in between the group of compounds that correspond to the chemical structures (A) and (B), in all their enantiomeric and/or isomeric forms.

Compound(s) A




wherein,

R₁ is an omega-3 or omega-6 fatty acid ester or omega-9 fatty acid ester

R₂ is an omega-3 or omega-6 fatty acid ester

Compound(s) B



wherein,

R₃ is an omega-3 or omega-6 or omega-9 fatty acid ester

R₄ is an omega-3 or omega-6 or omega-9 fatty acid ester or an oligosaccharide covalently bound.

This compounds A and B are able to deliver to the body an additional source of cerebrosides and/or sphingolipids not described to the date.

One of the embodiments is a process of microencapsulation characterized in that there exists at least one compound defined by the formulas (A) and/or (B); as well as a formulation of microcapsules to be used for the development of potential intelligence in foetus and breast feeding babies –through the maternal ingestion of a suitable alimentary vehicle in which the formulation of microcapsules is added- and in formulations of milk for babies and children, according the preceding claims, characterized in that contains omega-3 and omega-6 fatty acids in a ratio 0.5 – 10.0, preferably 1.4 – 5.7 and contains cerebrosides in a percentage of 0,005% - 1% and/or optionally compounds (A) and/or (B), also optionally omega-9 fatty acids; and also a formulation of microcapsules for its use in infant formula according to any suitable combination of preceding claims, characterized in that no omega-6 fatty acid is added and independently and optionally gamma-linolenic acid is added in a percentage of 1.25%.

Concerning the ratios of cerebrosides the formulation of microcapsules used to increase the development of the brain cortex and intelligence, is characterized in that it contains omega-3 and omega-6 fatty acids, preferably in a ratio 1.4 – 5.7 and contains also cerebrosides in a percentage of 0.005% - 1% and optionally compounds (A) and/or (B).

The fatty acids preferred for this invention refer to the group –also for those substituents of A and B-, not limited to: oleic, stearic, eicosapentanoic, docosahexanoic, docosapentanoic, linoleic, conjugated linoleic acids, gamma-linolenic, alpha-linolenic, dihomogamma-linolenic, arachidonic and oleic.

These FA may be conjugated with other compounds that provoke their liberation in the human body previous blood transport, being possible to be bonded (maintaining or not all their unsaturations) and/or be covalently bonded with glycerides –mono-, di-, and tri-glycerides preferably), phospholipids,

sphingolipids, myelin, amines, ethers, sugars, glycosides, oligosaccharides, nitrogenated and/or oxygenated and/or phosphorylated and/or sulfurated heterocycles or substituted aromatic rings.

The arachidonic acid is very unstable by virtue of its high unsaturations (4), as well as other UFAs, and our microcapsules protect the integrity of the original molecules up to its use by the consumer. In the sense of antioxidant protection we propose a formulation consisting in a dispersion of microcapsules characterized in that the active ingredients that are easily oxidable, in particular the unsaturated fatty acids, are protected by means of other active ingredients that can be defined by determined chemical structures or being extracts or juices with antioxidant properties, being the antioxidants, independently from their hydrophobicity in the water phase or in the oil phase, preferably in the phase where the easily oxidable material is present.

A singular aspect of the invention is the ability to release the active content, in a preferred embodiment at $\text{pH} < 3$ (thus, releasing the active ingredient only in the stomach). According an experimentally chosen combination of hydrocolloids (taken into account its biodegradability) it can be tailor-made microcapsules with no opening of the microcapsule's wall at pH higher than 3.5, microcapsules that the microcapsules' wall breaking (and subsequent liberation of the content) occurs quickly at pH lower than 3 or characterized in that the breakdown of the microcapsules' wall and the liberation of the content occurs in the conditions of animals' stomach, being the microcapsule's wall materials adequately chosen for the pH range of the stomach of the animal or its ability of enzyme digestion.

FA of long chain (more than 6 carbon atoms), are present in natural sources, w-6 and w-9 being common in plants, but w-3 are more difficult to find in plants, and they are predominant in fishes. Appart from usual (state of the art) sources of w-6 and w-9, other sources of w-3 are:

- (a) vegetable origin: Boraginaceae, (*Borago* spp., *Borago officinalis*); Linaceae (*Linum usitatissimum*, *Linum arvense*, *Linum sativum*); Onograceae (*Oenothera biennis*); Grossulariaceae (*Ribes nigrum*), Zea Mais, *Gossypium hirsutum*, *Carthamus tinctorius*, *Glycine max*.
- (b) algae preferably: Gracilariaceae (*Gracilaria* spp); Gigartinaceae (*Iridaea* spp.); Kallymeniaceae (*Callopyllis variegata*); Durvillaceae (*Durvillaea antarctica*); Solieriaceae (*Euchema cottoni*); Gelidiaceae (*Gelidium* spp); Lossoniaceae (*Lesonia nigrescens*); Gigartinaceae (*Gigartina* spp.); Lessoniaceae (*Macrocystis* spp.); Bangiaceae (*Porphyra* spp.); *Cryptocodinium* spp.
- (c) Animal origin, normally fish oil, preferably: Engaulidae (*Lycengraulis olidus*); Clupeidae (*Sardina pilchardus*); Scomberesocidae (*Scomberesox saurus scombroides*); Berycidae (*Beryx splendens*); Engraulidae (*Engraulis ringens*); Ophichthyidae (*Ophichthus* spp.); Serranidae (*Hemilutjanus macrophthalmus*); Scombridae (*Thunnus* spp., en especial, *Thunnus albacares*, *Thunnus alalunga*, *Thunnus obesus*); Sciaenidae (*Cynoscion analis*); Carcharinidae (*Prionace glauca*); Normanichthyidae (*Normanichthys crockeri*); Percichthyidae (*Polyprion oxygeneios*); Nototheniidae (*Dissostichus eleginoides*); Apogonidae (*Epigonus crassicaudus*); Branchiostegidae (*Prolatilus jugularis*); Scombridae (*Thunnus* spp., *Thunnus albacares*, *Thunnus alalunga*, *Thunnus obesus*, *Sarda* spp., *Sarda chiliensis*,

Scomber japonicus peruanus), Sciaenidae (Cynoscion analis), Carcharhinidae, Normanichthyidae (Normanichthys crockeri); Percichthyidae (Polyprion oxygeneios); Nototheniidae (Bacalao de profundidad); Apogonidae (Epigonus crassicaudus); Branchiostegidae (Prolatilus jugularis); Cheilodactylidae (Cheilodactylus gayi); Gadidae (Salpilota australis); Pomadasyidae; Scorpaenidae; Serranidae; Cyprinidae; Monacanthidae; Centrolophidae; Ophidiidae; Scorpaenidae; Coryphaenidae; Channichthyidae; Sciaenidae; Aplodactylidae; Carangidae (Trachurus symmetricus murphyi); Bothidae (Paralichthys microps); Mugilidae; Clupeidae; Priacanthidae; Merlucciidae (Merluccius gayi gayi, Merluccius australis); Macruridae (Macrurus magellanicus); Gadidae (Micromesistius australis); Girellidae; Trachichthyidae; Carangidae; Kyphosidae; Callorhynchidae; Labridae; Macrouridae; Atherinidae; Gobiesocidae; Alopeidae; Galaxiidae; Rajidae; Bramidae; Carangidae; Nototheniidae; Scianidae; Mugiloididae; Salmonidae (Salmo spp., Salmo salar, Oncorhynchus spp., Oncorhynchus kisutch, Oncorhynchus mykiss, Oncorhynchus tshawytscha); Clupeidae (Sardinops spp., Sardinops sagax, Clupea bentincki); Pomadasyidae; Gempylidae; Lamnidae (Isurus spp., Isurus oxyrinchus); Triakidae; Clinidae; Scopthalmidae; Labridae; and more preferably Atlantic mackerel, Engraulis encrasicolus, Pomatomus saltatrix, Sarda sarda, Sardina pilchardus, Brevoortia tyrannus, Brevoortia patronus, Chloroscombrus chrysurus, Auxis thazard, Scomber scombrus, Scomber japonicus, Alosa aestivalis, Clupea harengus, Etrumeus teres, Argentina silus, Ictalurus punctatus.

(d) microbial origin, preferably: Saccharomices cerevisiae, Escherichia coli, Schizochytrium spp., Thraustochytrium aureum, Thraustochytrium roseum, Thraustochytrium striatum, Mortierella spp., Phytium spp., Aspergillus spp. Aspergillus nidulans, Aspergillus sydowi, Fusarium spp., Fusarium equiseti, Fusarium oxysporum.

One of the embodiments of the invention is a microencapsulated formulation for increasing the neural development, specially the brain and more specially in unborn, newborn, babies and kids characterized in that at least it is present one of the compounds with the formula B and/or A.

Other embodiment is the use of a microencapsulated formulation for increasing the potential intelligence in unborn and babies feed with mother milk, by means of the consumption on the side of the milk-giving woman in an appropriate foodstuff where it is added the microencapsulated formulation. Also for infant food and milks, characterized in that it contains w-3 and w-6 in a ratio of 0.5-10 preferably 1.4-5.7, and moreover it contains cerebrosides in a percentage of 0.005% and 1% and/or optionally compounds A + B. There are many recommended ratios of w-3 to w-6, without a firm scientific base. On the other side there exist patents that cover all imaginable combinations of ratios. The inventors adopt a range more accepted by medical institutions from different countries. The novelty of the present invention is the incorporation of cerebrosides and optionally compounds A + B, as well a way to provide to the consumer UFAs without the presence of bad or off-aromas or degradation products of the UFAs. The inventors have verified that in an industrial process to prepare milk with w-3, the 50% of the initial content in w-3 is lost during homogenization and pasteurization. Our microcapsules, industrially, in the worst case, proven in a pilot plant, we obtain a maximum in

losses of w-3 of 7%. We claim as well a formulation of microcapsules for its use in infant formula characterized in that no omega-6 fatty acid is added and independently and optionally gamma-linolenic acid is added in a percentage of 1.25%. Also, in a preferred embodiment we use a microencapsulated formulation for increasing the development of the brain cortex and the intelligence, characterized in that contains omega-3 and omega-6 fatty acids in a ratio 0.5 – 10.0, preferably 1.4 – 5.7 and contains cerebrosides in a percentage of 0,005% - 1% and/or optionally compounds (A) and/or (B).

The inventors have formulated a beverage (soft drink) Beverage containing a formulation of microcapsules, characterized in that the beverage contains microcapsules, and the latter contain in the oil phase omega-6 and/or omega-3 fatty acids, optionally with antioxidants added in the aqueous phases of the microcapsule or in the oil phase of the microcapsule or in both and the beverage contains additionally flavours or extracts of: grape, pineapple, and at least a citric fruit, preferably selected from tangerine, orange, mandarin, lemon, lime, and the omega-3 and omega-6 fatty acids remain stable in the beverage after the industrial process, including customary microbiological stabilization processes like pasteurization, at least up to one month, with a loss of omega-3 less than 7%. After more than one hundred trials to try to maske the off-flavor of omega-3 sources, the inventors tried the best solution with a tasting panel that was not able to detect the presence of the aroma of fish oil or flax oil. Another embodiment of the invention is a juice containing microcapsules of our invention characterized in that (a) the microcapsules contain omega-3 fatty acids coming from a commercial formulation of edible linseed oil; (b) the oil phase contains the linseed oil and an emulsifier based on soja compounds; (c) the water phase contains a mix of different subclasses of hydrocolloids of the type alginates and/or Arabic gum and/or kappa-carrageenate and/or guar gum, also an edible primary emulsifier with HLB in between 10 and 14 and an edible viscosity modifier; (d) the pH of the formulation of microcapsules is 3 to 6, the particle size median of the freshly produced microcapsules is 1 – 10 µm; (e) the main ingredient of the juice is orange juice. Optionally the furits that constitute the juice are chosen from the group: citrics, pineapple, grape and in that contain (all data referred to 150 mL of juice) w-3 in the range 20-200 mg, w-6 in the range 10-100 mg and w-9 in the range of 5-50 mg; with a ration w-3 : w-6 of about 3:1.

Playing with the hydrocolloid or hydrogel type, the inventors are able to formulate microcapsules that are destroyed at low pH (like that present in the human stomach) or are resistant to low pHs (and can pass through the stomach –convenient for certain hormones like insulin- and the wall microcapsule being broken when the pH in the intestine is increased), as well as walls that can be attacked by bacteria (e.g., using starch as a wall materials, the amylases would destroy the wall), or by pressure by chewing, or to be gelified in the presence of salive, releasing a flavour (e.g., menthol) in a very fast way. Since in no way the invention is limited for human consume, the microcapsules may be designed for the conditions particular to each animal (e.g., the pig has many amylases in the mouth to the difference of the men, and a microcapsule formulated with starch as wall material would be appropriated to give to the food a better taste to increase the food ingestion, therefore, the benefit os the farmer).

The microcapsules and appropriate formulations are compatible and desirable for foods in which the active ingredients come from agriculture (term including fisheries and animals' farming)

“biological” and/or ecological”, because this falls in the line with a healthy diet without intervention of products strange to the nature. Obviously, in this embodiment, and in many others, all the materials must be edible.

In another embodiment, with an spirit completely contrary to the one said in the beforementioned paragraph, the formulation uses for the obtention of the active ingredients, GMOs, hybrid vegetal varieties or obtained by human selection, as well as microbiological cultures selected by any technique. This embodiment is possible but not desired because the consumers generally avoid GMOs.

Apart from alimentary uses, the microcapsules produced by our processes can be included in medicinal formulations, combined with active compounds not present in the microcapsules or being the active ingredients present in the microcapsules (or formulation of microcapsules) the only active ingredients of the medicinal preparation, including under the term medicinal preparation also materials for its use in radiology contrasts, seed for oncological radiotherapy, thermotherapy or therapy by irradiation with light of any wavelength. In a preferred embodiment, radiological contrasts are very appropriate to be combined (used as a.i.) with our microcapsules that allow the transit through the stomach without being degraded and finally excreted, for medical uses (e.g., detection of bleedings by virtue of the degradation of microcapsules' wall materials sensitive to enzymes of the blood plasma).

Because many of the healthy active ingredients are labile, specially to oxidation, an embodiment is to keep separated the capsules separated from the food or beverage until the final consumption of the product, optionally with a receptacle that by pressure liberates the microcapsules' formulation, preferably dried, to the food or beverage.

For a better understanding of the invention, 19 figures are enclosed, which explanation is better understood when reading the example to which they refer.

Description of the Figures. [NOT PRESENT IN THE PCT BUT MAYBE NEEDED FOR SOME COUNTRIES]

Figure 1 shows the first emulsion to be formed with different biologically active ingredients (3, 4, 5, 6), being 1a the oil phase (oil: 1) and 1b the water phase (2: water). 1b is added to 1a as arrows 7 and 8 show, forming the emulsion 1c, with water droplets 10 in the oil phase 9.

Figure 2 shows the addition (arrow 27) during the process of the hydrocolloid (26) solution 2b, to the former emulsion solution 1c, now represented after such addition by 2a. We can find in 2a the W/O/W emulsion-dispersion, the water continuous phase being 24, 11 representing the water in oil dispersed emulsion that will represent the core of the microcapsules, and 12 the inner water phase of the "oil" droplets 11.

Figure 3 represents the polymerization reaction of the hydrocolloids(s) taking place in the water phase.

Figure 4 is a more advanced status of polymerization where the hydrocolloids (14), apart from being polymerized are being cross-linked.

Figure 5 shows the addition of the protective colloid(s) 15, that will be integrated in the polymeric structure 14, being 5a the protective colloid(s) solution and 5b the representation of the incorporation of the protective colloid to the incipient microcapsules.

Figure 6 shows the solution of primary emulsifier 6a that is added to the continuous water phase (24) represented in Figure 2, 2a. 17 shows that this primary emulsifier (that may be composed of different types of state of the art emulsifiers for emulsions oil in water or mixtures of such emulsifiers with those used for oil in water emulsions) allows the breakdown on the half-formed microcapsules, allowing the reduction of the particle size.

In Figure 7 we show the final structure of a microcapsule that due to the process of breaking and reconstitution showed in Figure 6, may exist small microcapsules (25, 21) inside bigger microcapsules (22), showing also the protective colloid 18 and the polymerized and crosslinked hydrocolloid(s) 19. In 7b we have a microcapsule where an additional hydrocolloid (dotted line 40) has been incorporated (e.g., chitosans) to reinforce the microcapsules.

Figures 8 and 9 show typical particle size distribution of our microcapsules.

Figures 10 to 13 show typical τ vs. η viscosigrams of our formulated microcapsules.

Figures 14 to 16 show microscopic views of the microcapsules and materials enclosed therein or in the continuous phase.

Figure 17 represents the comparison of the temperature and shelf stability of omega 3 and omega 6 when microencapsulated as described in our invention (examples) vs. commercial "ready to add" omega-3 and omega-6 commercially available, showing an uncontestable better performance regarding stability of our microcapsules compared one the commercial product, in the standard conditions of the trial

Figure 18 shows typical and well described in the literature off-flavors and toxic and/or carcinogenic substances that appear when foodstuffs containing not well-protected UFAs are submitted to industrial processing or long storage.

Figure 19 shows the appearance of some of the compounds shown in Figure 18 in non-microencapsulated foodstuffs containing omega-3 and omega-6 fatty acids, measured by gas chromatography and mass spectrometry and flame ionization detection.

EXAMPLES

The following examples are given for illustrative purposes and they cannot be considered as a restriction to the claimed formulation, in so far, changes from the here presented examples are overcome easily in laboratory formulations and/or in bulk production.

Also, the applicant has developed proprietary methods to analyze formulations made by means of the herein disclosed procedures, in order to determine unambiguously, when a formulation has been done with the information provided in the present document. These methods of analysis are also available in order to comply with Health and Governmental regulations for approval of new-marketed products.

Example 1.

In this example we describe the active ingredients used to make a formulation suitable for its application to orange juice.

1.1.- *Ingredients*

<u>Oil Phase</u>	[%]
Flaxoil	25.00
Emulpur	1.00
<u>Water Phase</u>	
Dest. Water*	20.00
Rosemary extract	2.80
Juice from carrots	7.30
Orlistat (lipase inhibitor)	1.00

1.2.- *Encapsulation and emulsification ingredients*

	[%]
Alginate solution**	25.00
Guar gum (4% in water)	15.40
Lamegin	2.50
Keltrol	0.30

* plus 0.5 % CaCl₂, 0.1 % ascorbic acid, 0.08% nipagil [all in water].

** Alginate solution= 5 % Manucol LB in water

1.2 Process:

-oil phase: weigh in a bottle, homogenize in an ultrasonic

	bath
-water phase	weigh in a bottle, homogenize in an ultrasonic bath
-W/O emulsion	put the oil then the water phase in the reactor, make the emulsion with stirrer at 7350 rpm, 25 min
-(W/O)/W emulsion	add the alginate solution, stirrer at 350 rpm at 35°C
-Decrease of particle	shortly after add the arabic gum, stir at 8350 rpm at 35 °C
-Further decrease of particle size	shortly afterwards, add the Lamegin, Ultraturrax 8135 rpm at 35 °C
-Curing of the microcapsules	3000 rpm for 120min at 75 °C
-Addition of viscosity modifier	after 20 min add Keltrol, at 5000 rpm
-Cooling down	stop water bath, cooling down to 5-10 °C
-Fill up	fill up directly in package.

Physiochemical Parameters:

pH= 6.5

Particle size:

D (v;0,5): 12,57 µm [median] D (v;0,9): 26,39 µm [percentile 90]

Examples 2 to 11

In Table 1, we present a series of microencapsulation processes. These microencapsulations have been made following the general procedure described above. With the data provided in previous patents are in many cases not enough to reproduce or to get the claimed formulations.

Both components and results of the tests are shown in table 1.

Formulation components active ingredients are described, those of the oil phase and also those of the water phase. The data provided about particle size correspond to the percentile 50 –D (v; 0,5)- and percentile 90 –D (v; 0,9)-.

We can see in the last row the quality of the resulting formulation. As we can see, small changes in composition may lead to a bad formulated microencapsulated material.

Example 12

In the present embodiment, we show the release of microcapsules at a certain pH. Microcapsules break down at stomach pH, while the microcapsules stay intact in the yogurt, which is also acidic (but not as highly acidic as the stomach).

The objective of the present example is to test the release rate of microencapsulated riboflavin (according to the present invention) present in a probiotic yogurt.

The yogurt has been prepared (20 kg) in a traditional, hand-made, way, using an "in-house" culture of fermentation kept from the last yogurt production.

The composition of the formulation (percentage with respect to total active ingredients) is:

- Riboflavine 100 µg/kg yogurt (less than 0.1% of the total active ingredients)
- Lactobacillus casei 10% (solution in water of a culture with 500 colonies per cm²)
- Avena sativa extract 90%

The formulation has been prepared following the general procedure of encapsulation, with alginates as the cross-linked hydrocolloid and a mixture of Ceratonia siliqua gum and arabic gum as protective hydrocolloids.

A non-encapsulated material has been included in the experiment to show the differences, and also a blank sample.

- A) Test in acidic media (1 HCl, buffer at pH 2.5) – conditions in the stomach
- B) Test the delivery rate of vitamin B₂, in an isotonic solution at pH 4.0 – conditions in an organic yogurt –produced in an organic farm-.

A-Results in acidic media-

It is clearly shown, that release of Vitamin B₂ from the Formulation GAT 032541 occurs in stomach conditions.

The average amount of released Riboflavin happens after 30 min. is 21.5 µg/kg [it is said, a conversion of the weighted sample of ca. 30 – 40 %]; after 60 min., are released 25.7 µg/kg [it is said, a conversion of the weighted sample of ca. 40 – 50 %].

The release rate in non-encapsulated material is, as expected, higher. After 30 min., the average released amount of Vitamin B₂ is 46.8 % [it is said, 40 – 50 % of the weighted sample]; after 60 min., are released 47.2 µg/kg [it is said, a conversion of the weighted sample of ca. 65 – 75 %].

The blank did not show any release (gas-liquid chromatographic peak) of Riboflavin.

B-Results in yogurt media-

Formulation GAT 032541 does not release any vitamin B₂, while being in the yogurt, at least for one and a half month.

The non-encapsulated sample showed a slight release of 0.021 µg/g after 30 min., and 0.032 µg/g after 60 min.

The blank samples did not show any noticeable change in Vitamin B₂ content.

Example 13.

One of the innovative aspects of the present invention is its ability to keep the active ingredients stable for longer time with respect to the state in the art microencapsulation and even any other method of formulation. This obviously does not apply for stable active ingredients (e.g. minerals).

We have performed tests of storage ability while remaining the active ingredients unchanged.

The process of encapsulation is basically as the one presented in the example 1, with the exception that the secondary wall is formed with xanthan gum (from Fluka), the emulsifier is Softenol® 3767 (1%) and the viscosity modifier is Glycosperse® (1%), the source of w-3 and w-6 fatty acids was fish oil (Clupea harengus).

Results of this experiment are showed in the following table, where we appreciate that the stability of the fatty acids, for 60 days at 45° C is exceptional.

	Palmitic acid	Stearic acid	oleic acid	linoleic acid	alpha-linolenic acid	w-3 acids
	% in the oil	% in the oil	% in the oil	% in the oil	% in the oil	% in the oil
d=0	1,1	1,4	2,9	2,8	2,7	7,8
d=30; 4 °C	1,1	1,4	2,7	2,6	2,5	7,8
d=30; 25 °C	1,1	1,4	2,6	2,6	2,6	7,7
d=30; 45°C	1,1	1,3	2,6	2,5	2,5	7,7
d=60; 45°C	1,1	1,3	2,4	2,5	2,4	7,5

Example 14.

The major problem associated with developing new formulations is the difficulty to infer the actual results from past formulations. As far as many components (and quantities) may be present in a microencapsulation, the number of experiments needed for a good statistical validation is enormously high. We have overcome this problem with the state in the art statistical techniques associated to experimental design. We have used a Folded Plackett-Burman experimental design (we are interested only in the main factors, and not in interactions for the purpose of this analysis), with 3 center points and an acceptable level of error degrees of freedom (19). This accounts for 27 runs (instead of the 64 needed in a regular experimental design –all combinations-) in order to investigate the influence in the final formulation of:

- Oil phase (grape seed oil [50%] + salmon fish oil [50%]): 2 levels, 10%-30%
- Natural extract (grape marks [50%] + green tea decaffeinated [50%]): 2 levels, 10%-20%
- Alginate solution: 2 levels, 5%-10%
- Carrageen gum solution: 2 levels, 5%-10%
- Yucca glauca extract: 2 levels, 3%-5%
- homogenization: 2 levels, present-not present
- Spray drying: 2 levels, present-not present

The independent variable is in this case, a value that reflects the suitability of the microencapsulation for industrial purposes, in particular, to add to soft drinks. To evaluate this "acceptability index" we have used the expression:

$$AccIndex = \frac{(0.20 * ParticleSize + 0.30 * Density + 0.15 * UnreactedPolymers + 0.15 * DegreeMultiencapsulation + 0.20 * UnencapsulatedIngredients)}{1} * 100$$

We have developed, through a series of experiments a table that gives, for each Particle Size (and the other variables) a value in between 0 and 1. "Density" (not the actual meaning of density) may have value 0, because outside a defined range, the density is not considered; also, the

acceptability index depends of the constraints of the other variables (e.g., if the degree of unreacted polymers is higher than 40%, we give to the acceptability index a value of 0, no matter the value of the rest of the parameters). The constant values that account for the weight of each value have been developed specially for soft drinks. It is clear that behind these experimental design there is much work involved.

This way, we obtain (Statgraphics®) a randomized design as follows, being “-1” the lower level and “1” the higher level (last column, Acceptability Index):

run/test	Oil	Plant	Algin.	Xanth.	Yucca	Hom.	Spray	Acc.Index
1	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0
2	1,0	-1,0	-1,0	-1,0	1,0	-1,0	-1,0	10
3	1,0	-1,0	1,0	1,0	-1,0	1,0	-1,0	95
4	1,0	1,0	-1,0	1,0	1,0	-1,0	1,0	60
5	1,0	1,0	-1,0	-1,0	-1,0	1,0	-1,0	84
6	-1,0	-1,0	1,0	-1,0	1,0	1,0	1,0	32
7	1,0	-1,0	1,0	-1,0	-1,0	-1,0	1,0	20
8	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0
9	-1,0	1,0	1,0	1,0	-1,0	-1,0	-1,0	60
10	-1,0	-1,0	-1,0	1,0	-1,0	-1,0	1,0	30
11	-1,0	-1,0	1,0	1,0	1,0	-1,0	1,0	28
12	1,0	1,0	-1,0	1,0	-1,0	-1,0	-1,0	45
13	1,0	-1,0	1,0	1,0	1,0	-1,0	-1,0	31
14	-1,0	1,0	1,0	1,0	-1,0	1,0	1,0	69
15	-1,0	-1,0	-1,0	1,0	1,0	1,0	-1,0	85
16	1,0	-1,0	-1,0	-1,0	1,0	1,0	1,0	93
17	-1,0	1,0	-1,0	-1,0	1,0	-1,0	1,0	15
18	-1,0	-1,0	-1,0	-1,0	-1,0	-1,0	-1,0	7
19	1,0	-1,0	-1,0	1,0	-1,0	1,0	1,0	54
20	-1,0	1,0	-1,0	1,0	1,0	1,0	-1,0	61
21	-1,0	-1,0	1,0	-1,0	-1,0	1,0	-1,0	12
22	1,0	1,0	1,0	1,0	1,0	1,0	1,0	69
23	1,0	1,0	1,0	-1,0	1,0	1,0	-1,0	81
24	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0
25	-1,0	1,0	1,0	-1,0	1,0	-1,0	-1,0	20
26	1,0	1,0	1,0	-1,0	-1,0	-1,0	1,0	17
27	-1,0	1,0	-1,0	-1,0	-1,0	1,0	1,0	72

The results of the ANOVA analysis showed in Table 2 show that all the parameters studied influence the final product acceptability. This is indicated by the p-value (<0.05 in all cases), as any

skilled in statistics would appreciate. Thus, in developing a formulation of health improving soft drinks, we cannot neglect any of the effects of all the variables tested.

It is remarkable that most important parameter in this type of microencapsulation for soft drinks, the homogenization has extreme influence in the final microcapsules.

Example 15.

We have tested the stability of a formulation (according to example 9, improving the previous results with addition of a secondary emulsifier –span 65, 5%-) of spores of *Bacillus subtilis*. Later we tested that actually the spores were viable (seeding in potato dextrose-agar with development of colonies).

Results of the stability of the microcapsules, based on the stability of the particle size of the dispersion, at different aging times, are shown in Fig. 9. There it is show the distribution of the particle size of the microcapsules (the outer diameter, when in the case of multienapsulation). The different curves obey to different storage times and temperatures.

A= initial (time=0, T= 25 °C)

B= after 60 days at 3 °C

C= after 60 days at 25 °C

D= after 90 days at 25 °C

The shape of the curves is homogeneous, meaning that the breakdown of the capsules has not occurred.

Note that the particle size is that of the microcapsules (values are plotted when the counter has arrived to 1,000,000 particle size measurements). If we had spores released into the media, the shape of the curve would have changed, and also shifted to the left, because the spores of *Bacillus subtilis* are in the range 1 to 2 µm.

Example 16.

In the method of analysis of formulations, we have obtained the diagrams of viscosity vs. shear stress.

The peak showed in Fig. 10 to 12 is characteristic of our formulation. It indicates that the microencapsulated formulation diminishes progressively its internal structure due to the force applied (shear stress), but after a period of time (force) while the cohesive forces that keep the macromolecular structure of the formulation stable are broken (namely, until the peak shown). Note that the microcapsules are not broken, rather, the structure that keeps the microcapsules in dispersed, without precipitation, coacervation or any distortion of the formulation. When the macromolecular cohesive forces (mainly electrostatic forces) are low (Fig. 13) we do not observe any peak, but a progressive decrease in the viscosity with shear stress applied, because, in such lower viscosity range, the cohesive forces are easily broken. This type of behavior is acceptable in our formulation, but is less desirable than the one depicted in Figs. 10 to 12. When the curves are almost linear (the

lower curve of Fig. 13), this means that we are dealing with a liquid with Newtonian behavior, the latter not being convenient either for our formulation.

Example 17.

In this example we show another embodiment of the invention, where there are encapsulated minerals.

In the microphotograph (Fig. 14) we can appreciate the inclusion of inorganic minerals inside the core of a microcapsule. Selenium (from a suitable yeast culture) and zinc citrate have been added. It is clearly shown (ovale and arrow) a crystal of zinc citrate formed in the oil phase, at the same time that we observe the effect of multiencapsulation, where the small particles around are authentic microcapsules enclosed inside the bigger microcapsule that contains the crystals.

Example 18.

In the present example we show two different types of microcapsules.

In the microphotograph (Fig. 15), we appreciate single microcapsules (inside the rectangle) and also a microcapsule with more microcapsules inside (inside the oval). The adjustment of the light and focusing must be done in such a way the two compared types of microcapsules are at the same distance from the objective. Then, a big difference in the refraction of the light shows the degree of microencapsulation.

Claims

1.- Continuous multi-microencapsulation process, by means of in situ interfacial polymerization of biologically active materials characterized in that,

(a) in a first step it is added to an oil phase [that contains optionally at least a biologically active material] a water phase containing a polymerization initiator and optionally, at least a biologically active material; further exists at least one surfactant in at least one of the two mentioned phases, and there exists a biologically active material in at least one of the two phases,

(b) In a second step, it is added [to (a)] a solution or dispersion in water that contains at least one hydrocolloid, this producing a phase inversion and the hydrocolloid begins to be deposited and polymerized on the walls of the new formed drops [consisting in a water in oil emulsion], occurring also a cross-linking of the hydrocolloid polymers, optionally in the presence of cations,

(c) In a third step, it is added [to (b)] a solution or dispersion in water that contains at least one protective colloid, that begins to be deposited on the surface of the drops of water in oil, and to polymerize and cross-link with itself and the hydrocolloid,

(d) In a fourth step, it is added [to (c)] a solution or dispersion in water of a primary surfactant that allows a reduction of the size of the water in oil drops,

(e) In a fifth step, during the process of reduction of size, the partially formed microcapsules are deagglomerated and reagglomerated, happening eventually an enclosure of drops inside bigger drops (multi-microencapsulation),

(f) When enough time has passed in order that the oil [water in oil] drops are covered by at least one hydrocolloid and at least a protective colloid, the temperature is increased in order to strengthen the wall of the mentioned drops; at this time the drops are already microcapsules or multi-microcapsules suspended in water.

(g) Optionally, the formulation is dried for obtaining dust, optionally it is reformulated by means of state of the art techniques to obtain (or to mix the microcapsules with) wettable powders, gels, cosmetic creams or medicinal, bath products, microorganism media; optionally additives are added (optionally antiagglomerating agents) for microcapsules' dried formulations.

(h) All the process –except optionally step (g)- is carried out under continuous agitation.

2.- Process for the preparation of a suspension of microcapsules characterized in that:

(a) Two different solutions (Fig.1) 1a (oil) and 1b (water) are mixed by addition of 1b to 1a, these solutions containing active ingredients and optionally free or sequestered cations to be liberated later,

(b) Thanks to a food emulsifier that can be in 1a or in 1b, an emulsion of water drops (10) into the oil phase (9) is formed. This step is finished with the formation of emulsion 1c, where in the oil phase (9) are solubilized or dispersed –preferably liposoluble- active ingredients; it is also formed an oil in water emulsion, with the water droplets (10) containing –preferably hydrosoluble- active ingredients, being optional that the solubility [of the active ingredients] in water or in oil is modified by derivatization of the active ingredient(s),

(c) Then, it is added to existing emulsion [1c] the solution 2b, having 2b at least one hydrocolloid [able to be polymerized and cross-linked] and optionally containing at least one active ingredient,

(d) It follows a phase inversion, having then dispersed drops (11) that are an emulsion of water (12) in oil, dispersed in the continuous phase (24), namely, water,

(e) when the polymerization and cross-linking reactions are deemed to be finalized, reaching a reduction of particle size to about 1-30 m, the temperature that remained at about 30-70 °C is raised to 60-100 °C.

(f) Finally it is added a food grade viscosity modifier.

(g) Optionally, the formulation may be spray-dried or any state of the art technique, and to be collected to form dry powders, self-emulsifiable powders, gels, creams or any other form that may contain them, including oil dispersions, as well as to be submitted to a liophyllization unit operation.

3.- Process of microencapsulation of biologically active materials, according claims 1 or 2 characterized in that both the hydrocolloid(s) and the protective colloid(s) are added together in the form of an aqueous solution or dispersion, saving the step (d) of claim 1, because the protective colloid is present in the solution described in claim 1 step (c) or claim 2 step (e).

4.- Process of microencapsulation of biologically active materials according claim 1, characterized in that the protective colloid(s) belong to the chemical group of hydrocolloids.

5.- Process of microencapsulation of biologically active materials according claims 1 and 2 characterized in that the hydrocolloid(s) and the protective colloids are preferably chosen among the group of: chitosans, starch, dextrans, cyclodextrins, celluloses, lignin, pectines, agar, alginates, carrageens, gelatins, guar gum, arabic gum, gelatin, tragacanth, lignosulfonates, Caraya gum, Ceratonia siliqua gum, saponines, xantan gum, seed gums, galactomanans, arabanogalactams, beta-glucans, inulin, psyllium, acacia gum; in all their isomeric and stereochemical forms, in all their variations regarding quantity and proportion of monomers or oligomers constituting the hydrocolloid, in all presentation forms, as salts of metal cations or nitrogenated, sulfurated or phosphorinated compounds, as well as any derivatization form of the aforementioned hydrocolloids.

6.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the primary emulsifier has a hydrophilic – lipophylic balance of 9 to 16, preferably 12 to 14.

7.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that in the first emulsion formed the oil droplets have a particle size of 50-500 µm, preferably 70-200 µm.

8.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the finally formed microcapsules (7b) have a particle size of 0.1-100 µm, preferably 1-30 µm, more preferably 1-5 µm.

9.-Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the formed microcapsules (7b) have a particle size that changes with time by aggregation being the particle size optimum just when the microcapsules' formulation is going to be used.

10.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the revolutions per minute of the agitator employed for forming the emulsion(s) and reducing the particle size are in the range 3000-25000, being this value higher at the time of forming the first emulsion and lower when the microcapsules are finally formed, and when is added the viscosity modifier.

11.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that there are used two types of agitators, one with teeth and the other with anchor.

12.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that at least one hydrocolloid forming the wall is substituted by a hydrogel, optionally, albumins, alginates, polycarboxilates, poli-L-lactid, starches and derivatives of all of them.

13.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the aqueous solution of hydrocolloid contains a binary or ternary mixture of the hydrocolloids selected according to claim 5 and/or hydrogel(s) mentioned in claim 12.

14.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the aqueous solution of hydrocolloid contains a binary or ternary mixture of the hydrocolloids selected according to claim 5.

15.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the microcapsules or the aqueous phase in that they are disperse, contain compounds that help or stabilize structurally the structure of the microcapsule.

16.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the continuous aqueous phase in that the microcapsules are dispersed, contains biologically active materials, that have been added in the form of a dissolution, dispersion or emulsion in any of the solutions of: hydrocolloid(s), protective colloid(s) primary emulsifier(s) being these solutions used according suitable preceding claims.

17.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that it is carried out in at least one of the following conditions: under vacuum, reduced pressure, in the presence of an inert gas (optionally nitrogen, helium), protected from any wavelength, in sterile conditions.

18.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the aqueous solutions or dispersions are substituted by solutions or dispersion: (i) based in aqueous extracts, (ii) with a content in alcohols (with a molecular weight of 144 or less) not higher than 40%, (iii) of compounds soluble or dispersible in water.

19.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the oil phase comprises a hydrogenated oil or a wax, eventually honey.

20.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the water and/or oil phase act as thermal regulator, stabilizing the microcapsules and biologically active materials contained in the liquid phases (both inside and outside of the microcapsules) against temperature changes, optionally adding compounds to diminish the freezing point or increase the freezing point, being possible to add these compounds to the oil phase to modify the thermal properties of the formulation itself or the microcapsules.

21.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that in any step of the process is added a microbiological stabilizer to the oil and/or water phases.

22.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that in any step of the process is added a state of the art microbiological stabilizer for a dry formulation of microcapsules (eventually lyophilized, in dust form, in granular form).

23.- Process of microencapsulation according any suitable combination of the preceding claims, characterized in that after the drying of the microcapsules, these are reformulated and dispersed in an oil phase or in a gel or in any semi-solid material or ethanolic solution or organic solvent.

24.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the resulting microcapsules are used in any foodstuff (solid or liquid or including gases), optionally but not limited to: cereals and derived (optionally muesli, cereals for milk), pastry shop, dairy products, nutritional supplements, sugars and derived (optionally chocolates, sweet, nougats, marzipans), sweet dietary (with low level of calories), in régime foods and for diabetics, oils and derived, milky and derived, eggs, vegetables and vegetables, vegetables, fruits, tubers and derived, eatable shafts, snacks, appetizers, eatable roots (optionally licorice), bay and wild products, preserves of fruits, dry fruits, meats, sausages, fish, shellfish and crustaceans and their preserves, alcoholic and not alcoholic drinks, carbonated drinks or not carbonated, juices, syrups, nectars, spices, condiments, pre-cooked foods, pre-processed foods (frozen mass of bread), pizzas, honey.

25.- Process of microencapsulation according any suitable combination of the preceding claims characterized in that as biologically active materials are choser at least a compound chosen from the group of omega-3 fattay acids, optionally also omea6 and/or omega 9, coming from fish of flax oil and

these omega fatty acids are accompanied optionally by antioxidants –preferably from green tea- and the microcapsules produced thereof are used in bakery, cookies, muesli or cereal products with high fiber content, being the total content, with respect 100 grams of final product (e.g., a cookie), of omega 3 plus omega 6 (if present) plus omega 9 (if present) about 50 mg to 400 mg.

26.- Process of microencapsulation of biologically active materials according any preceding claims, characterized in that the main purpose of microencapsulation is to prevent the release of undesirable aromas or flavours to the consumer (human or not human), optionally fish aromas and flavours and those derived from other biologically active ingredients.

27.- Microcapsules produced by a continuous process of microencapsulation, characterized in that (a) contain biologically active materials (b) the microcapsules wall is made by a mixture of at least two hydrocolloids (including hydrogels as particular case of hydrocolloids), such mixture polymerized and cross-linked, (c) the polymerization and cross-linking grade and the nature of hydrocolloids influence the release rate and the protection against oxygen and/or light and/or temperature, (d) the microcapsules have in their core an emulsion water in oil, existing optionally biologically active materials in the oil phase, optionally in the water phases and optionally in all continuous phases, and moreover, the core of the microcapsules may contain smaller microcapsules (multi-microencapsulation possible at least to five degrees), (e) the mean particle size measured with a Master Sizer type laser equipment is 0.1-100 μm , preferably 1-10 μm (f) they are produced by a continuous process of multi-microencapsulation process by interfacial in-situ polymerization process.

28.- Microcapsules produced according any of the preceding claims where the biologically active materials are released by at least a factor belonging to the group: pH, temperature, pressure, ionic force, osmosis, volatilization, presence of compounds that dissolve the microcapsules wall (eventually enzymes or chemical compounds).

29.- Formulation of microcapsules according any appropriate combination of the preceding claims characterized in that it resists usual industrial unit operations regarding microorganisms' control, noxious microorganisms and/or not desired in the final formulation freshly done or possible colonizer microorganisms of the formulation or foodstuff to which the formulation is to be added being this unit operations eventually: sterilization, microbiological stabilization, pasteurization, UHT, ozonization, UV or gamma ray treatment, chemical antimicrobial agents.

30.- Microcapsules according any appropriate combination of the preceding claims characterized in that they are used for providing anabolites and/or nutrients in microbiological cultures in a constant or quasi-constant rate.

31.- Microcapsules according any appropriate combination of the preceding claims characterized in that they are used for providing anabolites and/or nutrients in microbiological cultures, and at least an active ingredient is liberated at certain media pH.

32.- Microcapsules according any appropriate combination of the preceding claims characterized in that they are used for providing anabolites and/or nutrients in microbiological cultures, and at least an active ingredient is liberated at certain media concentration of at least one enzyme.

33.- Microcapsules according any appropriate combination of the preceding claims characterized in that they are used for providing anabolites and/or nutrients in microbiological cultures, and at least an active ingredient is liberated at certain concentration of a chemical, preferably ethanol, that provokes the liberation of the biologically active ingredient.

34.- Microcapsules according any appropriate combination of the preceding claims characterized in that they are used for providing beneficial for the health materials and the microcapsules are added to natural or synthetic sweeteners, salt, pepper, spices and other condiments, in such a way that the addition of such condiments to other foodstuffs increment the nutritive value or the health benefit of such foodstuffs.

35.- Microcapsules according any appropriate combination of the preceding claims characterized in that they contain an UV- protector and/or blocker and/or stabilizer.

36.- Formulation of microcapsules according to any appropriate combination of the preceding claims because the active ingredients are chosen from the group: green tea, black tea, cocoa, red wine or grapes or marcs, cider, apple juice or apple, cereal germ or bran, carrots, chili, allium, horseradish (in particular spicy horseradish).

37.- Process of microencapsulation of biologically active materials beneficial for the human or other animals' health, according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active compound present in the formulation is preferably chosen from the groups:

- (a) Flavonoids in general and derivatives: anthocyanidins, pro-anthocyanidins, oligomer-procyanidine, isoflavones, chalcones, catechin, epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, eriocitrin, narirutin, rutin, naringin, myricitrin, hesperidin, myricetin, eriodictyol, fisetin, quercetin, naringenin, luteolin, hesperitin, kaempferol, isorhamnetin, apigenin, rhamnetin, galangin, quercitrin, quercetin, diosmetin, taxifolin, galandin, biochanin A, genistein, eriodictyol, chrysin, hydroxytyrosol, oleuropein, glabridine, licochalcone, daidzein, matairesinol, secoisolariciresinol, enterodiol, enterolactone, equol, desmethylangolensin, luteoferol, luteolinidin, apiferol, apigenidin, leucocyanidin, taxifolin, pelargonidin; and derivatives thereof;
- (b) phenolic acids in general and derivatives (preferably esters, glycosides, rutinoides and amines): gallic, sinapic, syringic, caffeic, chlorogenic, ferulic, (o-, m- or p-) coumaric, guaiacol, (o-, m- or p-) cresol, 4-ethylphenol, 4-vinylguaiacol, eugenol, p-hydroxybenzoic, procatechuic,

- vanillic, hydroxycinnamic, tanins in general tannins, ellagitannins, gallotannins; and derivatives thereof;
- (c) eststructurally combined amides comprising hydroxycinnamic acids and anthranilic acids (avenanthramides), avenasterol, hydroxycinnamic acids and long-chain fatty acids or alcohols –and derivatives thereof-; indoleamines (e.g. melatonin); inulin, glutation;
 - (d) terpenoids in general and derivatives, monoterpenes, diterpenes, sesquiterpenes, triterpenes, tetraterpenes including the carotenoids: alfa-carotene, phytoene, cyclo-artenol, beta-carotene, ionone, zeaxanthin, capsanthin, astaxanthin, canthaxantin, violaxanthin, mutatoxanthin, luteoxanthin, auroxanthin, neoxanthin, apo-carotinal, xanthophylls; and derivatives thereof;
 - (e) commonly synthesized antioxidants for its use in foodstuffs and derivatives of the type of butylhydroxyanisol, 2,6-di-tert-butylhydroxytoluene, tert-butylhydroquinone, 2,6-di-tert-butylhydroquinone, 2,6-diterbutyl-4-hydroxymethylphenol, 2,4,5-trihidroxibutyrophenone; and derivatives thereof, tocopherols (e.g. alpha, beta, gamma and delta tocopherols –and derivatives thereof-; Tocotrienols (alpha, beta, gamma and delta tocotrienols –and derivatives thereof-); Tocochromanols;
 - (f) alpha-lipoic acid; coenzyme Q-10; vitamins; aminoacids (preferably L-arginine, cistina and cysteine) and their corresponding organic polymers like oligopeptides, peptides –preferably carnosine, carnitine, glutathion-; enzymes; enzyme inhibitors (preferably phenolases or oxigenases or lipooxygenasas or lipases inhibitors;
 - (g) minerals and oligoelements, especially those involved in redox processes in vivo like selenium, zinc, magnesium;

38.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active compounds present in the formulation preferably has its origin in: *Medicago sativa*, *Pimena officinalis*, *Hibiscus abelmoschus*, *Angelica archangelica*, *Galipea officinalis*, *Pimpinella anisum*, *Ferula foetida*, *Ferula asafetida*, *Melissa officinalis*, *Myroxylon pereirae*, *Ocimum basilicum*, *Pimenta acris*, *Citrus aurantium bergamia*, *Prunus amygdalus*, *Citrus aurantium*, *Citrus aurantium amara*, *Piper nigrum*, *Prunus spinosa*, *Aniba rosaeodora*, *Camelia oleifera*, *Camelia sinensis*, *Carum carvi*, *Elettaria cardamomum*, *Ceratonia siliqua*, *Daucus carota*, *Dacus carota sativa*, *Cascarilla*, *Apium graveolens*, *Anthemis nobilis*, *Matricaria chamomilla*, *Anthemis nobilis*, *Anthriscus cerefolium*, *Cichorium intybus*, *Cinnamomum* spp., *Cinnamomum zeylanicum*, *Cymbopogon nardus*, *Salvia sclarea*, *Trifolium pratense*, *Theobroma cacao*, *Coffea arabica*, *Coriandrium sativum*, *Cuminum cyminum*, *Taraxacum officinale*, *Sambucus nigra*, *Edelweiss*, *Helichrysum italicum*, *Foeniculum vulgare*, *Trigonella foenumgraecum*, *Arabidopsis* spp., *Zingiber officinale*, *Citrus grandis*, *Psidium guajava*, *Humulus lupulus*, *Marrubium vulgare*, *Monarda punctata*, *Hyssopus officinalis*, *Jasminum officinale*, *Jasminum grandiflorum*, *Juniperus* spp. *Juniperus communis*, *Eucalyptus officinalis*, *Cola acuminata*, *Laurus nobilis*, *Lavandula* spp. *Lavandula hybrida*, *Taxus baccata*, *Citrus medica limonum*, *Myristica fragrans*, *Marjorana hortensis*, *Thymus* spp., *Thymus officinalis*, *Thymus mastichina*, *Ilex paraguarensis*, *Chamomilla recutita*, *Saccharum officinarum*, *Myristica fragrans*, *Allium cepa*, *Citrus aurantium dulcis*, *Carum petroselinum*, *Mentha pulegium*, *Mentha piperita*, *Pimenta officinalis*, *Chimaphila umbellata*,

Punica granatum, *Pelargonium* spp., *Pelargonium graveolens*, *Rosmarinus officinalis*, *Crocus sativus*, *Salvia* app., *Salvia officinalis*, *Mentha spicata*, *Mentha viridis*, *Satureia hortensis*, *Satureja hortensis*, *Origanum majorana*, *Tamarindus indica*, *Citrus reticulata*, *Artemisia dracunculus*, *Thea sinensis*, *Thymus vulgaris*, *Polianthes tuberosa*, *Curcuma longa*, *Prunus serotina*, *Thymus serpyllum*, *Satureja Montana*, *Cananga odorata*, *Curcuma zedoaria*, *Plantago major*, *Adansonia digitata*, *Ananas comosus*, *Artocarpus altilis*, *Carica papaya*, *Lycopersicon esculentum*, *Cephalophus* spp., *Vaccinium myrtillus*, *Thymus aragonensis*, *Thymus* spp., *Citrus aurantiifolia*, *Citrus paradisi*, *Cucumis melo*, *Cucurbita* spp., *Vitis* spp., *Vitis vinifera*, *Mangifera indica*, *Lamiaceae* (*Coleus*, *Hedeoma*, *Hyptis*, *Leonurus*, *Leucas*, *Lycopus*, *Marrubium*, *Mentha*, *Monarda*, *Perilla*, *Prunella*, *Salvia*, *Stachys*, *Teucrium*, *Thymus*), *Cannabis* spp., *Digitalis lanata*, *Adonis vernalis*, *Aesculus hippocastanum*, *Frazinus rhychophylla*, *Agrimonia eupatoria*, *Rauwolfia serpentina*, *Andrographis paniculata*, *Areca catechu*, *Atropa belladonna*, *Berberis vulgaris*, *Ardisia japonica*, *Betula alba*, *Ananas comosus*, *Camellia sinensis*, *Cinnamomum camphora*, *Camptotheca acuminata*, *Potentilla fragarioides*, *Erythroxylum coca*, *Papaver somniferum*, *Colchicum autumnale*, *Claviceps purpurea*, *Digitalis purpurea*, *Digitalis lanata*, *Glaucium flavum*, *Papaver somniferum*, *Gossypium* spp., *Hyoscyamus niger*, *Camptotheca acuminata*, *Piper methysticum*, *Lobelia inflata*, *Crotalaria sessiliflora*, *Nicotiana tabacum*, *Physostigma venenosum*, *Ephedra sinica*, *Cinchona ledgeriana*, *Rhododendron molle*, *Datura* spp., *Taxus brevifolia*, *Strychnos nux-vomica*, *Stevia rebaudiana*, *Theobroma cacao*, *Valeriana officinalis*, *Pausinystalia yohimbe*, *Ephedra* spp. *Crataegus oxyacantha*, *Hamamelis virginiana*, *Hydrastis Canadensis*, *Hypericum perforatum*, *Potentilla erecta*, *Ledum palustre*, *Salvia officinalis*, *Chamomilla recutita*, *Arctostaphylos uva*, *Eucommia ulmoides*, *Mytilus galloprovincialis*, *Diplazium esculentum*, *Manihot utilissima*, *Sauropous androgynus*, *Terminalia arjuna*, *Iberis amara*, *Crataegus* spp., *Arbutus unedo*, *Cynara scolymus*, *Amaranthus caudatus*, *Alchornea laxiflora*, *Alpinia officinarum*, *Xanthophyllomyces dendrorhous*, *Crataegus monogyna*, *Taxus yunnanensis*, *Bacopa monniera*, *Cistus albidus*, *Ocimum basilicum*, *Rosmarinus officinalis*, *Thymus vulgaris*, *Bixa orellana*, *Centella asiatica*, *Urtica dioica*, *Agrocybe aegerita*, *Crataegus laevigata*, *Satureja hortensis*, *Crocus sativus*, *Coccinia indica*, *Brugia malayi*, *Rubus* spp., *Silybum marianum*, *Cannabis* spp., *Cannabis sativa*, *Hypericum perforatum*, *Rhus coriaria*, *Olea europaea*, *Cyclopia intermedia*, *Ginkgo biloba*, *Lentinus lepideus*, *Pseudomonas putida*, *Sargassum micracanthum*, *Pinus radiata*, *Pinus* sp., *Phaseolus mungo*, *Cicer arietinum*, *Vigna sinensis*, *Phaseolus aureus*, *Dolichos lablab*, *Cajanus cajan*, *Vicia faba*, *Dolichos biflorus*, *Phaseolus lunatus*, *Phaseolus aconitifolius*, *Pisum sativum*, *Psophocarpus tetragonolobus*, *Arachis hypogaea*, *Brassica* spp., *Brassica campestris*, *Brassica napus*, *Valeriana officinalis*, *Echinacea purpurea*, *Echinacea pallida*, *Echinacea angustifolia*, *Glycyrrhiza glabra*, *Seronea repens*, *Vaccinium macrocarpon*, *Tanacetum parthenium*, *Tanacetum parthenium*, *Vaccinium macrocarpon*, cereals, seed fruits, silvestre bays, leguminosae, green tea, black tea and microorganisms able to produce long-chained unsaturated fatty acids.

39.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials consist in probiotic bacteria.


40.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials present in the formulation consist in probiotic bacteria, optionally acid lactic-bacteria and more preferably chosen among the group: *Lactobacillus casei.*, *L. acidophilus*, *L. rhamnosus*, *L. paracasei*, *L. gasseri*, *L. fermentum*, *L. plantarum*, *L. salivarius*, *L. crispatus*, *L. bulgaricus*, *L. fermentum*, *L. reuteri*, *Bifidobacterium infantis*, *B. bifidum*, *Streptococcus thermophilus*, *S. bovis*, *Enterococcus durans*, *E. faecalis*, *E. Gallinarum*, *Escherichia coli*, *Propionibacterium freudenreichii*, or bacteria or fungi or yeasts genetically modified in that the beneficial genes -characterizing the beneficial properties of probiotic bacteria- have been inserted.

41.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials present in the formulation consist in probiotic yeasts, preferably chosen from the group: *Saccharomyces cerevisiae*, *Kluyveromices marxianus*, *Rhodotorula rubra*, *Sporobolomyces puniceus*, *Aureobasidium pullulans*, *Leucosporidium scotti*.

42.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials present in the formulation consist in probiotic fungi, preferably those fungi present in or coincident or coming from cheeses.

43.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials is chosen among the group of compounds represented by the molecular structures (A) and (B) in all their stereochemical and isomeric variations:

Compound(s) A




wherein,

R₁ is an omega-3 or omega-6 fatty acid esterified

R₂ is an omega-3 or omega-6 fatty acid esterified

Compound(s) B



wherein,

R₃ is an omega-3 or omega-6 fatty acid esterified

R₄ is an omega-3 or omega-6 fatty acid esterified

44.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials consists preferably in at least one unsaturated long-chain fatty acid (at least 6 Carbon atoms), in any isomeric and/or stereochemical configuration, as well as any derivatives thereof (preferably esters, ethers, glycerides, phospholipids, sphingolipids, and more preferably, diglycerides, triglycerides, phospholipids or compounds A and/or B): steradionic, eicosapentaenoic, docosahexaenoic, docosapentaenoic, linoleic and conjugated linoleic acids, linolenic, gamma-linolenic, alfa-linoleic, dihomogamma-linolenic, arachidonic, oleic acid.

45.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that the fatty acids are chosen preferably from the group of acids: oleic, steradionic, eicosapentaneic, docosahexaenoic, linoleic, conjugated linoleic, gamma-linolenic, alfa-linolenic, dihomogamma-linolenic, arachidonic.

46.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that at least one of the biologically active materials consists preferably in at least one unsaturated long-chain fatty acid (of at least 6 Carbon atoms) that are preferably conjugated, keeping or not keeping all or part the unsaturated bonds unchanged with respect the natural compounds, and/or bound covalently with glycerides –more preferably with monoglycerides, diglycerides, triglycerides' esters-, phospholipids, sphingolipids, myelin, amines, amides, ethers, sugars, oligosaccharides, polysaccharides, nitrogenated-, phosphorated-, oxygenated-, sulfurated- heterocycles, substituted aromatic rings.

47.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that the unsaturated long-chain fatty acid (of at least 6 Carbon atoms) are selected by its medicinal virtues.

48.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that the unsaturated long-chain fatty acid (of at least 6 Carbon atoms) come from the following natural sources or from genetically modify organisms of the following natural sources, preferably from:

(a) vegetable origin: Boraginaceae, (*Borago* spp., *Borago officinalis*); Linaceae (*Linum usitatissimum*, *Linum arvense*, *Linum sativum*); Onograceae (*Oenothera biennis*); Grossulariaceae (*Ribes nigrum*), *Zea Mais*, *Gossypium hirsutum*, *Carthamus tinctorius*, *Glycine max*.

(b) algae preferably: Gracilariceae (*Gracilaria* spp); Gigartinaceae (*Iridaea* spp.); Kallymeniaceae (*Callopyllis variegata*); Durvillaceae (*Durvillaea antarctica*); Solieriaceae (*Euchema cottoni*); Gelidiaceae (*Gelidium* spp); Lossoniaceae (*Lesonia nigrescens*); Gigantinaceae (*Gigartina* spp.); Lessoniaceae (*Macrocystis* spp.); Bangiaceae (*Porphyra* spp.); *Cryptothecodinium* spp.

(c) Animal origin, normally fish oil, preferably: Engaulidae (*Lycengraulis olidus*); Clupeidae (*Sardina pilchardus*); Scomberesocidae (*Scomberesox saurus scombroides*); Berycidae (*Beryx splendens*); Engraulidae (*Engraulis ringens*); Ophichthyidae (*Ophichthus* spp.); Serranidae (*Hemilutjanus macrophthalmus*); Scombridae (*Thunnus* spp., en especial, *Thunnus albacares*, *Thunnus alalunga*, *Thunnus obesus*); Sciaenidae (*Cynoscion analis*); Carcharhinidae (*Prionace glauca*); Normanichthyidae (*Normanichthys crockeri*); Percichthyidae (*Polyprion oxygeneios*); Nototheniidae (*Dissostichus eleginoides*); Apogonidae (*Epigonus crassicaudus*); Branchiostegidae (*Prolatilus jugularis*); Scombridae (*Thunnus* spp., *Thunnus albacares*, *Thunnus alalunga*, *Thunnus obesus*, *Sarda* spp., *Sarda chiliensis*, *Scomber japonicus peruanus*), Sciaenidae (*Cynoscion analis*), Carcharhinidae, Normanichthyidae (*Normanichthys crockeri*); Percichthyidae (*Polyprion oxygeneios*); Nototheniidae (*Bacalao de profundidad*); Apogonidae (*Epigonus crassicaudus*); Branchiostegidae (*Prolatilus jugularis*); Cheilodactylidae (*Cheilodactylus gayi*); Gadidae (*Salilota australis*); Pomadasyidae; Scorpaenidae; Serranidae; Cyprinidae; Monacanthidae; Centrolophidae; Ophidiidae; Scorpaenidae; Coryphaenidae; Channichthyidae; Sciaenidae; Aplodactylidae; Carangidae (*Trachurus symmetricus murphyi*); Bothidae (*Paralichthys microps*); Mugilidae; Clupeidae; Priacathidae; Merlucciidae (*Merluccius gayi gayi*, *Merluccius australis*); Macruronidae (*Macruronus magellanicus*); Gadidae (*Micromesistius australis*); Girellidae; Trachichthyidae; Carangidae; Kyphosidae; Callorhynchidae; Labridae; Macrouridae; Atherinidae; Gobiesocidae; Alopeidae; Galaxiidae; Rajidae; Bramidae; Carangidae; Nototheniidae; Scianidae; Mugiloididae; Salmonidae (*Salmo* spp., *Salmo salar*, *Oncorhynchus* spp., *Oncorhynchus kisutch*, *Oncorhynchus mykiss*, *Oncorhynchus tshawytscha*); Clupeidae (*Sardinops* spp., *Sardinops sagax*, *Clupea bentincki*); Pomadasyidae; Gempylidae; Lamnidae (*Isurus* spp., *Isurus oxyrinchus*); Triakidae; Clinidae; Scopthalmidae; Labridae; and more preferably Atlantic mackerel, *Engraulis encrasicolus*, *Pomatomus saltatrix*, *Sarda sarda*, *Sardina pilchardus*, *Brevoortia tyrannus*, *Brevoortia patronus*, *Chloroscombrus chrysurus*, *Auxis thazard*, *Scomber scombrus*, *Scomber japonicus*, *Alosa aestivalis*, *Clupea harengus*, *Etrumeus teres*, *Argentina silus*, *Ictalurus punctatus*.

(d) microbial origin, preferably: *Saccharomices cerevisiae*, *Escherichia coli*, *Schizochytrium* spp., *Thraustochytrium aureum*, *Thraustochytrium roseum*, *Thraustochytrium striatum*, *Mortierella* spp.,

Phytium spp., Aspergillus spp. Aspergillus nidulans, Aspergillus sydowi, Fusarium spp., Fusarium equiseti, Fusarium oxysporum.

49.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that the unsaturated fatty acids omega-3 and/or omega-6 and/or omega 9 that are incorporated in the claim 1 or 2, come from commercial products to be incorporated in foodstuffs, based on fish or vegetable or microbial oils or mixes thereof.

50.- Process of microencapsulation of biologically active materials according to any suitable combination of the preceding claims, characterized in that the compounds omega-3, omega-6, cerebrosides, and optionally omega-9, are combined to improve the development or maintenance or recovery of the brain cortex.

51.- Formulation consisting in a suspension of microcapsules produced according to any suitable combination of the preceding claims, characterized in that contains as active compound, or as an additional active compound, linoleic acid, conjugated linoleic acid, arachidonic acid, docosaexenoic acid, eicosapentenoic acid, steradionic acid, alfa-linolenic acid, dihomogammalinolenic acid, oleic acid, linolenic acid, in all their isomeric and/or stereochemical configurations.

52.- Formulation of microcapsules to be used for the neuronal development, specially the brain, and more specially in foetus, new born, babies and children characterized in that there exists at least one compound defined by the formulas (A) and/or (B).

53.- Formulation of microcapsules to be used for the development of potential intelligence in foetus and breast feeding babies –through the maternal ingestion of a suitable alimentary vehicle in which the formulation of microcapsules is added- and in formulations of milk for babies and children, according the preceding claims, characterized in that contains omega-3 and omega-6 fatty acids in a ratio 0.5 – 10.0, preferably 1.4 – 5.7 and contains cerebrosides in a percentage of 0,005% - 1% and/or optionally compounds (A) and/or (B), also optionally omega-9 fatty acids.

54.- Formulation of microcapsules for its use in infant formula according to any suitable combination of preceding claims, characterized in that no omega-6 fatty acid is added and independently and optionally gamma-linolenic acid is added in a percentage of 1.25%.

55.- Formulation of microcapsules used to increase the development of the brain cortex and intelligence, characterized in that it contains omega-3 and omega-6 fatty acids, preferably in a ratio of 0.5-10 preferably 1.4 – 5.7 and contains also cerebrosides in a percentage of 0.005% - 1% and optionally compounds (A) and/or (B).

56.- Beverage containing a formulation of microcapsules, produced according to any suitable combination of the preceding claims, characterized in that the beverage contains microcapsules, and

the latter contain in the oil phase omega-6 and/or omega-3 fatty acids, optionally with antioxidants added in the aqueous phases of the microcapsule or in the oil phase of the microcapsule or in both and the beverage contains additionally flavours or extracts of: grape, pineapple, and at least a citric fruit, preferably selected from tangerine, orange, mandarin, lemon, lime, and the omega-3 and omega-6 fatty acids remain stable in the beverage after the industrial process, including customary microbiological stabilization processes like pasteurization, at least up to one month, with a loss of omega-3 less than 7%.

57.- Microcapsules produced according to any suitable combination of the preceding claims, characterized in that they are stable (no opening of the microcapsule's wall) at pH higher than 3.5.

58.- Microcapsules produced according to any suitable combination of the preceding claims characterized in that the microcapsules' wall (and subsequent liberation of the content) occurs quickly at pH lower than 3.

59.- Microcapsules formed according to the process described in claim 1, characterized in that the breakdown of the microcapsules' wall and the liberation of the content occur in the conditions of the human stomach by virtue of lowering the pH.

60.- Microcapsules formed according to the process described in claim 1, characterized in that the breakdown of the microcapsules' wall and the liberation of the content occur in the conditions of the human stomach by enzymatic digestion.

61.- Microcapsules formed according to the process described in claim 1, characterized in that the breakdown of the microcapsules' wall and the liberation of the content occurs in the conditions of animals' stomach, being the microcapsule's wall materials adequately chosen for the pH range of the stomach of the animal or its ability of enzyme digestion.

62.- Microcapsules suitable for their ingestion, containing ingredients of the type omega-3 and/or omega-6 and/or omega-9 and/or sphingolipids, produced according to any suitable combination of the preceding claims characterized in that the microcapsules are included in an infant formulation in a proportion according to the national or international public medical recommendations, stabilized with vitamin E and/or vitamin C, as well derivatives of both vitamins (specially those derivatives that influence the lipophilic or hydrophilic character).

63.- Microcapsules according to any suitable combination of the preceding claims characterized in that the active ingredients are hormones.

64.- Microcapsules according to any suitable combination of the preceding claims characterized in that the hydrocolloids and protective colloids are chosen according to the pH range of the animal's stomach, considering that animals of the same genus and species have the same pH range.

65.- Microcapsules according any suitable combination of the preceding claims characterized in that the hydrocolloids and protective colloids are chosen according the pH range of the animal's stomach, including the human, considering that animals of the same genus and species have the same pH range, being released at least one active compound in the stomach.

66.- Microcapsules according any suitable combination of preceding claims characterized in that are used in acid foodstuffs preferably yogurts, juices, soft drinks.

67.- Microcapsules according any suitable combination of preceding claims characterized in that the breakdown of the microcapsule's wall occurs at least because the attack of at least one enzyme, eventually activated at a certain pH.

68.- Microcapsules according any suitable combination of preceding claims characterized in that the breakdown of the microcapsule's wall, totally or partly, is produced because of enzyme(s), eventually by the pH, present in the animal's mouth, including the human.

69.- Formulation of microcapsules for its use in infant formula according to any suitable combination of the preceding claims, characterized in that all the active ingredients and optionally all components of the formulation have been produced by biological and/or ecological agriculture, including the term agriculture fisheries and farming.

70.- Formulation of microcapsules for its use in infant formula according to any suitable combination of the preceding claims, characterized in that for obtaining the active ingredient(s) have been used genetically modified organisms, hybrid vegetable varieties or obtained by human selection, as well as microbiological cultures obtained by any means.

71.- Microcapsules according any suitable combination of the preceding claims characterized in that they are used in foodstuffs for animals, especially cattle, aviculture, fisheries and pets.

72.- Microcapsules according any suitable combination of the preceding claims characterized in that they are used in medicinal formulas, being combined with active ingredients not present in the microcapsules or being the active ingredients present in the microcapsules or formulation of microcapsules the unique active ingredients of the medicinal formula, including under the term medicinal formula materials used for contrast in radiology, seed for radiotherapy, thermotherapy or therapy with light of any wavelength.

73.- Microcapsules according any suitable combination of the preceding claims characterized in that they are added to para-pharmaceutic products of any composition, being the active ingredients of the microcapsules present in any concentration in the para-pharmaceutic product.

74.- Alimentary formulation containing microcapsules formed with edible materials containing active ingredients suitable for alimentary use, characterized in that the microcapsules are added to the alimentary formulation (any type of foodstuff or nutritional supplement) just at the time of consumption, thanks to a physical separation in between the microcapsules and the foodstuff that is eliminated at the time of consumption.

75.- Alimentary formulation containing microcapsules, the latter containing active ingredients, characterized in that the microcapsules are added to the alimentary formulation just at the time of consumption, by means of a physical separation during the shelf storage of the alimentary formulation of the microcapsules and the rest of the alimentary formulation by means of a barrier of membrane; being produced the addition of the microcapsules to the alimentary formulation by breakdown of said barrier or membrane in the previous moment before consumption or in a suitable time frame to allow a correct dispersion of the microcapsules in the alimentary formulation; in the case of beverages those microcapsules are preferably enclosed in a receptacle and are dispersed into the beverage by means of externally applied pressure on the receptacle and breakdown of the membrane that separates the microcapsules from the beverage, preferably being that receptacle present in the cap of the beverage container.

76.- Microcapsules according any suitable combination of the preceding claims characterized in that the microcapsule's wall material(s) are dissolved or degraded or liberate the active materials when the microcapsules are in the mouth of the consumer (human or other animals), being the consumer able to appreciate the organoleptic qualities of at least one microencapsulated material.

77.- Microcapsules produced according claim 51 characterized in that at least one of the hydrocolloids present in the wall or the unique compound of the wall is a hydrogel or a polymer highly soluble and/or gelificable with the moisture present in the mouth of the consumer (being human or other animal).

78.- Formulation of microcapsules for its use in infant formula according to any suitable combination of the preceding claims, characterized in that all the materials used and present in the final formulation of the microcapsules are approved alimentary use or edible.

79.- Formulation of microcapsules for its use in infant formula according to any suitable combination of the preceding claims, characterized in that all the materials used and present in the final formulation of the microcapsules are approved alimentary use, being the latter considered according to the legislation corresponding to the Country or Region where the formulation of microcapsules are produced and/or consumed.

80.- Juice containing microcapsules produced according any suitable combination of the preceding claims characterized in that (a) the microcapsules contain omega-3 fatty acids coming from a commercial formulation of edible linseed oil; (b) the oil phase contains the linseed oil and an emulsifier based on soja compounds; (c) the water phase contains a mix of different subclasses of hydrocolloids

of the type alginates and/or Arabic gum and/or kappa-carrageenate and/or guar gum, also an edible primary emulsifier with HLB in between 10 and 14 and an edible viscosity modifier; (d) the pH of the formulation of microcapsules is 3 to 6, the particle size median of the freshly produced microcapsules is 1 – 10 μm ; (e) the main ingredient of the juice is orange juice.

81.- Juice according claim 80 characterized in that the fruits are selected from citric fruits, pineapple, grape.

82.- Juice according claims 83 and 84 characterized in that contains (referred to 150 mL of juice) omega-3 in the range 20-200 mg, omega-6 in the range 10-100 mg and omega-9 in the range 5-50 mg; with a ratio of omega-3 to omega-6 of about 3 to 1.

83.- Formulation consisting in a dispersion of microcapsules according any suitable combination of the preceding claims, characterized in that the active ingredients that are easily oxidable, in particular the unsaturated fatty acids, are protected by means of other active ingredients that can be defined by determined chemical structures or being extracts or juices with antioxidant properties, being the antioxidants, independently from their hydrophobicity in the water phase or in the oil phase, preferably in the phase where the easily oxidable material is present.


Fig. 1

Fig. 2




Fig. 3





Fig.4



14


Fig. 5


Fig.6



Fig. 7

Fig.8




Fig. 9






Fig. 10**Fig. 11**



Fig. 12**Fig. 13**

Fig.14




Fig. 15




Fig. 16





Fig.17


Fig.18

Fig.19